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ABSTRACT 
The Zucker fatty (fa/fa) rat inherits a defective leptin receptor with impaired leptin signaling. 
Fatties grow at the same rate as their littermates for the first 22 days of age, and then suddenly 
begin to grow at a much higher rate. This corresponds with the emergence of robust hyperphagia 
in the fatty rat and leads to overt obesity within days. This striking change in energy balance 
regulation makes it possible to determine which sets of genes are regulated by the fatty mutation 
before and after the onset of hyperphagia. Genechip rnicroarrays were used to screen inguinal 
adipose tissue mRNA from wildtype and fatty rats at 20 days of age (before the emergence of 
hyperphagia) and 24 days of age (after the emergence of hyperphagia). Differentially expressed 
transcripts from several pathways were validated by real time quantitative reverse transcription 
polymerase chain reaction (RT-PCR). Transcripts associated with lipogenic pathways, including 
fatty acid synthase, malic enzyme, transketolase, glycerol 3-phosphate acyltransferase, insulin 
induced gene 1, and farnesyl diphosphate synthase, were expressed at similar levels in wildtypes 
and fatty rats before the onset of hyperphagia, but were highly induced in fatty rats after the onset 
of hyperphagia. A notable exception was stearoyt CoA desaturase 1, which converts saturated 
fatty acids synthesized by tipogenic pathways into monounsaturated fatty acids. Scd1 was 
upregulated in fatties 10.6-fold before hyperphagia emerged, and after the onset of hyperphagia, 
SCD1 expression increased 5.7-fold in fatty rats. This suggests that Scd1 is regulated 
independent of lipogenesis before the onset of hyperphagia, but is also developmentally 
upregulated. Leptin, lipoprotein lipase and PPARy mRNAs were also elevated prior to the onset 
of hyperphagia and may share a common regulatory pathway with stearoyl CoA desaturase 1. 
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CHAPTER 1. LITERATURE REVIEW 
Over the past 20 years the obesity crisis has grown to epidemic proportions. Despite 
heightened interest, little is actually known regarding obesity and its development, particularly the 
development of childhood obesity. This literature review seeks to shed light on the 
developmental factors of obesity and their potential roles in the occurrence of obesity. The 
following literature review begins with an overview of obesity and the resulting epidemic. To 
provide greater insight into how obesity occurs, the developmental stages of obesity are then 
discussed. In examining the developmental stages, the importance of the development of obesity 
becomes apparent. The paper then conveys the field's current understanding of the role of 
adipose tissue and various hormonal, nutritional and transcriptional regulations that play into the 
formation of obesity. The literature review concludes with a detailed look into the animal model. -
OBESITY: THE NEW EPIDEMIC 
Change in the Prevalence of Obesity over Time 
It has just been over the past 20 years the obesity epidemic has transpired. Though the 
origin for the increase in obesity is unclear, a shift has occurred in the primary causes of morbidity 
and mortality that parallels the spread of obesity. Infectious diseases such as pneumonia and 
tuberculosis have given way to chronic diseases such as cardiovascular disease and stroke as 
the primary public health problems (1-3). Researchers claim that the shift of cause of morbidity 
and mortality is due to modernization and a variety of socioeconomic factors, contributing to the 
rise in obesity and ultimately resulting in an increase in chronic disease (4,5). Overweight, 
defined as increased body weight in relation to height compared to a standard of acceptable or 
desirable weight, and obesity, defined as an accumulation of adipose tissue in relation to lean are 
known to be directly associated with a large number of chronic illnesses (6). According to the 
Center for Disease Control, 7 of 10 American deaths are a result of chronic disease a value that 
parallels the rise of individuals classified as overweight or obese in the United States (7). 
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The numbers of individuals classified as overweight and obese is increasing to disturbing 
proportions. Worldwide, over 700 million adults are overweight and more than 300 million are 
clinically obese. According to 1999-2000 NHANES data, it is estimated that 33% of adult 
Americans are overweight and that 31% of adults are ·clinically obese. Thus, over half of all 
adults in the United States are either overweight or obese, an increase of 8% since NHANES Ill. 
Specifically focusing on obesity, the prevalence of adults classified as obese has more than 
doubled since NHANES II data (8). 
Though the statistics for the prevalence of overweight and obesity in adults is alarming, 
even more frightening are the statistics regarding the prevalence of overweight and obesity of the 
youth. Worldwide it is estimated that 17.6 million children under the age of 5 are overweight (6). 
10% of children aged 2 to 5 years old are overweight and 16% of children (over 9 million) aged 6 
to 19 years old are overweight - a 45% increase since NHANES Ill (1988-1994) (9,10). Since 
1980, children classified as overweight aged 6-11 has more than doubled and the rate for 12-19 
year olds has more than tripled (7,8). The implications childhood obesity has on adult obesity 
and its associated correlation with chronic disease has become a major public health concern. 
Use of BMI as a Classifier 
Determining ones BMI is one of many screening tools used to indicate weight status and 
predict risk of disease in adults (individuals 20 years of age and older). BMI shows body weight 
adjusted• for height, specifically weight in kilograms is divided by height in meters times itself 
(kg/m2). The ranges of BMI are based on the effect body weight has on disease and death (table 
1). Overweight, or a BMI greater than 25.0, is correlated with chronic conditions such as 
hypertension, hypercholesterolemia, cardiovascular disease, diabetes, osteoarthritis, and various 
cancers. Moreover, a widely held belief is that obesity results in premature death. However, 
because BMI is calculated from weight and height only, often times it is not an accurate indicator 
of body fat mass (6). 
Prediction of BMI and the classification schema differs from adults in children and teens. 
With children and teens BMI is based upon age, or 'BMl-for-age', due to the increased rate of 
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Table 1. BMI classification for adults. 
BMI weight status obesity class 
> 18.5 Underweight 
1 8.5 - 24.9 Normal 
25.0 - 29.9 Overweight 
30.0 - 34.9 Obesity 
35.0 - 39.9 Obesity II 
�40 Extreme Obesity 1 1 1  
3 
growth that occurs during the developmental years. BMl-for.,age is based on gender and age 
specific charts - BMl-for-age is plotted on gender specific growth charts. Growth charts are then 
used to identify growth percentiles classifying children as underweight, risk for overweight and 
overweight (table 2). Though this method simply classifies children, rather than addressing their 
risk for disease, it allows us to monitor trends in childhood obesity. The monitoring of childhood 
obesity is pertinent in that it is directly related_ to risk factors for later development of heart 
disease, hyperlipidemia, hyperinsulinemia, hypertension , early atherosclerosis, etc. (11 ). 
Health Consequences of Overweight and Obesity 
Debilitating disease such as respiratory trouble, musculoskeletal problems, skin 
problems, infertility, etc. are associated with obesity. Additionally, obesity puts individuals at 
increased risk for conditions related to cardiovascular disease, insulin resistance and some forms 
of cancer (3,5, 12, 13). For example, through a 10 year follow up of the Nurses' Health Study and 
the Health Professionals Follow-up Study, Field et al found that both men and women with a BMI 
of :2:35.0 are about 20 times more likely to develop diabetes, compared to those with BMl's of 
18.5-24.9. Furthermore, overweight adults (BMI of 25.0-29.9) were more than 3 times as likely to 
develop diabetes, compared to their leaner peers. The risk of developing diabetes, gallstones, 
hypertension and heart disease increased in both men and women in response to the severity of 
overweight (5). The numerous consequences of childhood obesity are now coming to light. 
Recent studies suggest that obese children are often the target of prejudice and discrimination 
and thus, more likely to develop physiological problems such as low self-esteem and various 
behavioral problems. Overweight children have a tendency to be taller with advanced bone age. 
Overweight girls are at increased risk of early pubertal development while overweight boys are at 
risk for delayed pubertal development. Furthermore, the influence that childhood obesity has on 
acquiring adult obesity has been the subject of substantial research (12, 14, 15). Overweight 
children are more than two times as likely to become overweight adults compared to non-obese 
children and concurrently are at increased risk of suffering from the various chronic disease seen 
in adults discussed above (13, 14). Moreover, children are now starting to suffer from what were 
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Table 2. BMI classification for children .  
BM I-for-age 
< 5th Percentile 
85th - 951h Percentile 
�95th Percentile 
5 
weight status 
Underweight 
At risk for overweight 
Overweight 
once though to be adulthood disease. For example, an increasing number of children are 
developing type 2 diabetes, once referred to as "adult onset obesity" (6). Additionally, obese 
children are at increased risk for asthma, hyperlipidemia, cholecystitis, hypertension, etc. (16). 
The biology of obesity is complex and includes overconsumption of energy, the existence 
of a sedentary lifestyle and various genetic influences. Energy balance is controllable at two 
levels: intake and expenditure. Thus, if energy intake exceeds energy expenditure excess energy 
is stored in the form of triglycerides in adipose tissue. Overtime, excess intake coupled with 
insufficient physical activity results in the accumulation of body fat (1, 17, 18) .  Dietz asserts that 
the occurrence of environmental factors during pre and postnatal development has a permanent 
influence on normal growth. Accordingly, three specific periods for the development of obesity 
have been defined: the prenatal period, the period of adiposity rebound and the period of 
adolescence. Deitz claims that when physiological alterations occur during these critical periods 
of development individuals are at an increased risk for developing obesity later in life (16, 19). It is 
for this precise reason focus on the development of obesity is crucial. 
THE PHYSIOLOGICAL FOUNDATION: GENETICS AND THE DEVELOPMENT OF OBESITY 
The obesity epidemic and the heaith risk associated with obesity warrants the current 
interest in critical periods for obesity development. Because childhood obesity, more often than 
not, precedes adulthood obesity it is imperative that we thoroughly understand the mechanisms 
of obesity during the developmental years. Thorough understanding of the critical periods of 
development, of their origin, their mechanisms and how obesity ensues, presents a knowledge 
that may be applied to the treatment and prevention of obesity. Long standing research illustrates 
that obesity has both a genetic and a behavioral component. In the study of obesity, scholars 
argue that three critical periods are vital in predicting obesity: prenatal, adiposity rebound and 
adolescence. The discussion below provides a short definition and summary of each of these 
stages. Because this research focuses on the early development of obesity and the physiological 
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mechanisms that influence weight gain, after the brief discussior, of the stages attention shifts to 
a detailed look at the mechanisms influencing anomalies during early gestation. 
The Three Critical Periods of Obesity 
As mentioned, researchers suggest three specific stages of life that are especially 
susceptible to risk. Three specific phases of childhood development have been identified as 
critical periods during which various environmental factors influence growth and development. 
These periods are: the prenatal period including early infancy, the period of adiposity rebound 
which occurs between ages five and seven, and the period of adolescence. It is believed that 
when physiological alterations occur during these periods, individuals are at an increased risk for 
subsequent obesity (16,19). To prevent the likelihood of obesity it is necessary to understand 
these critical periods of development and recognize the multiple factors that influence them. 
Prenatal and Early Infancy 
The first critical period encompasses the prenatal period and early infancy. Increasing 
evidence is showing a relationship between fetal development and adulthood obesity. The 
prenatal period encompasses three trimesters: the first, lasting from week one to 13, the second, 
week 14 to 27 and the third trimester from week 28 to birth. Physiological alterations during any 
of these periods may result in an underdeveloped fetus and subsequent repercussions resulting 
in weight gain and fat mass accumulation (19-22). 
For example, the development of the brain, specifically the hypothalamus, occurs during 
the first and second trimester. The hypothalamus is responsible for the control of blood pressure, 
thermoregulation, energy balance, etc. through its action in is in response to neural inputs and 
circulating factors. These factors, such as hormones and substrates, inform the hypothalamus on 
the metabolic status of the body to which the hypothalamus responds. For example, during the 
fasted state the hypothalamus signals an increase in appetite stimulating factors such as Npy, 
MCH and glucocorticoids. During the fed state the circulation of appetite suppressing regulators 
such as CCK, a-MSH and leptin are increased (20). It has been found that an insufficient supply 
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of nutrient related substrates results in the underdevelopment of the hypothalamus, thus 
jeopardizing its ability to function properly (19-22). 
Another example of a critical period of prenatal development that may be influenced by 
physiological factors is during the second and third trimester. During this time period there is a 
12-fold increase in total body fat and adipocyte replication occurs at an accelerated rate. It has 
been observed that in early gestation fetal triglyceride stores are of similar composition and 
influenced by maternal stores. This demonstrates a direct link of the mother's nutritional status 
during gestation and her unborn child (16). 
Adiposity Rebound 
The second critical period, the period of adiposity rebound, is defined as the point of life 
at which a child is at minimum BMI. Adiposity rebound occurs at about six years of age (ranging 
from three to seven) and is the period before the second rise of adiposity and accelerated 
development occurs in children. Children experience accelerated growth from month one to 
month eight resulting in a rapid increase in BMI. At month nine, growth and BMI reach a plateau 
that continues until age five to six years at which point children experience a gradual increase of 
BMI through adolescence. 
Various studies regarding the age of adiposity rebound have provided valuable 
information. The Fels Longitudinal Study ultimately found an inverse relationship between the 
age of adiposity rebound and BMI in those at 18 years - the younger the age of adiposity 
rebound occurred the higher the BMI at 18. Additionally, adult obesity rates are increased 20% in 
individuals who experienced early adiposity rebound compared to those who are experience 
adiposity rebound at an older age (23). Thus, the point at which adiposity rebound occurs 
influences obesity in adolescence and adulthood - the earlier the adiposity rebound occurs, the 
higher the BMI in adolescence and adulthood (23,24). 
Though several hypotheses have been proposed regarding the influencing factors of 
adiposity rebound, the most common is associated with environmental factors and learned 
behavior. Adiposity rebound occurs at a time during which children are learning behaviors 
associated with energy intake, thus it is believed there is a corresponding relationship between 
adiposity rebound and parental control of energy intake. It seems the more parental control 
regulating energy intake, the less the children are able to regulate energy intake themselves. 
Children with parents more controlling of their intake have shown less ability to self-regulate 
energy intake compared to children given the freedom to control the amount they choose to eat 
(25,26). 
Adolescence 
The third and last defined period for critical development is adolescence. As discussed 
earlier, there is a strong correlation between obesity at this age and likelihood of adulthood 
obesity. Through a retrospective cohort study, Whitaker et al found that the likelihood of obesity 
as an adult increased more than 50% if the child was older than six years old and obese with no 
significant differences between boys and girls (15,23). Additionally, Guo et al found that BMI 
values during adolescence are important risk factors for the presence of adult overweight or 
obesity - children with BMI values at the 95th percentile had a 62-98% likelihood of becoming 
overweight by 35 years of age (12). Lastly, the Minneapolis Children's Blood Pressure Study, 
which monitored children from about 7 years of age to 23 years of age found a direct relation 
between excess weight gain during childhood and adult cardiovascular disease. This study also 
showed that height, weight, and BMI measured in early childhood is significantly associated with 
body size in young adulthood (27). The consequences of childhood obesity encompass 
psychosocial and medical aspects during the developmental years that continue into adulthood. 
There is considerable interest in these three critical periods: prenatal, adiposity rebound 
and adolescence that has provided useful knowledge regarding the development of obesity, 
particularly the research regarding prenatal development. This work is necessary because is 
provides the potential to offer opportunities for obesity prevention, and a way of understanding the 
mechanisms by which energy balance is regulated. Notwithstanding, the importance of the 
adiposity rebound and adolescent stages as determinants of obesity, this research focuses on the 
mechanisms influencing anomalies during early gestation in the development of obesity. Hence, 
the remainder of this section discusses specific examples regarding conditions occurring during 
early infancy that contribute to obesity. 
Early Infancy Development: A More In-depth Look 
With regards to body fat development, adipose tissue hypertrophy's during the first year 
of extra-uterine life. Size of the child at birth and feeding during the first year is critical in that the 
adipocytes of obese children continue to undergo hypertrophy, compared to non-obese children 
who experience little change in adipocyte volume. Because the second and third trimester, as 
well as the first year of life, is a critical period for the development of adipocyte and fat mass, 
alterations in normal development as a result of physiological factors can have long lasting affects 
on fat mass and adipocyte size in children. 
A popular example of the effects of physiological alterations during prenatal and early 
infancy development is demonstrated through the Dutch famine study of 1944-1945. This natural 
experiment looked at the prevalence of obesity in the offspring's of women exposed to a famine 
for 5 months in which total caloric consumption ranged from 400 to 1,000 kcal/day. At 19 years of 
age, the rate of obesity was higher in males who had been exposed to the famine during the first 
part of gestation compared to males exposed to the famine during the last trimester or immediate 
postnatal period. From this it has been concluded that the limitation of essential metabolic 
nutrients during the first and second trimester, specifically during the development of the 
hypothalamus, puts individuals at an increased risk of obesity later in life. On the other hand, 
when nutrients are limited during the third trimester and the first few months of life, during 
adipocyte replication and fat accumulation, individuals have increased chances for leanness later 
in life (19,28). Alterations of the intrauterine environment may result in a predisposition to 
obesity. The period of gestation and early infancy is a critical period for the development of 
obesity proving further investigation into mechanisms developing during this period is warranted. 
In sum, three critical periods of development in which environmental factors influence 
proper development have been identified. This knowledge presents us with a foundation in the 
basic mechanisms of development. It is from this foundation that knowledge must progress so 
that there is a more complete understanding of the mechanisms influencing weight gain and 
subsequently obesity in the developmental years and into adulthood. More complete knowledge 
provides the opportunity for treatment and prevention of obesity. Additionally, the loss of 
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significant weight as an adult is rare, thus prevention and treatment of obesity in childhood is 
essential. In sum, it can be concluded that while some individuals are predisposed to obesity as 
a result of environmental factors such as the overconsumption of energy and the existence of a 
sedentary lifestyle, others are predisposed to obesity as a result of genetic influences. This 
research seeks to extend our understanding of the early developmental influences on obesity with 
regards to the developmental mechanisms that activate various pathways, contributing to the 
development of obesity. 
The Genetics Behind the Development of Obesity 
With regards to genetics, obesity can result from single gene defects or polygenic gene 
defects in which each gene contributes to the disorder (29,30). Much has been learned with 
regards to the genetic influences of obesity as a result of the observation of monozygotic twins 
and the hereditability of fat mass (40-70%) (29). Additionally, various studies have shown there 
to be a stronger biological influence in the development of obesity compared to environmental in 
that the weight of adopted children tends to be closer to the biological parents versus the adopted 
parents (31 ). 
To date, six single-gene mutations and more than 40 Mendelian disorders have been 
discovered associated with obesity in humans (32). Various genetic disease that exhibit signs of 
morbid obesity in young children including Prader-Willi syndrome, Proopiomelanocortin, Bardet­
Biedl syndrome, Cohen's syndrome and Alstrom syndrome (29). Because environmental factors 
may be manipulated to prevent weight gain and promote weight loss it is important to identify and 
assume control of these factors, thus manipulating the outcome. Likewise, because genes are 
inherited with which we have little control over, it is important to understand the influence of 
genes to further understand the mechanisms of obesity and thus, develop methods for treatment 
and prevention of obesity. 
PWS 
Prader-Willi syndrome, the most common genetic syndrome of obesity, is a disorder that 
occurs from lack of expression of genes on chromosome 15, specifically region 15q11-q13. With 
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PWS, the natural expression of maternal alleles in this region is suppressed as a result of 
genomic imprinting during gametogenesis. Subsequently, it is vital that the genes are inherited 
paternally for proper expression to occur. However, in PWS the paternal genes are silenced, 
defective or deleted through maternal uniparental disomy. With maternal UPD two copies of the 
silenced maternal chromosome 15 are inherited (33). 
The major characteristics of those affected by PWS include hyperphagia, hypogonadism 
and growth hormone deficiency, indicating dysfunction of the hypothalamus, and results in morbid 
obesity. Development of PWS children is stunted until 6 months of age. From birth to about 6 
months, PWS children exhibit feeding difficulties including suckling problems and have little 
appetite, often times resulting in failure-to-thrive. In contrast, from years one to six, PWS children 
experience a rapid onset of robust hyperphagia, continuing into the adult years. PWS children 
eat excessively and do not respond to feelings of satiety as normal children. From these 
observations it may be assumed that the various pathways that mediate hyperphagia are not 
developed within the first few months of life. It seems the pathways that mediate hyperphagia are 
developed within the first few years of life resulting in the onset of hyperphagia after the first year. 
Without strict diet and weight control, PWS individuals eventually suffer from various obesity­
related morbidities including cardiopulmonary disease, type 2 diabetes, premature death, etc. 
Little is understood regarding the cause of PWS, however due to the symptoms 
observed in PWS individuals, there appears to be abnormalities in hypothalamic pathways. PWS 
individuals experience normal leptin secretion, in proportion to fat mass, CCK secretion, and 
there are no abnormalities in the distribution of NPY, AGRP and GHRH or the response to 
obesity. From this it could be assumed that PWS individuals would experience similar responses 
to satiety as people without the disorder, however hyperphagia continues (33,34). It seems 
abnormalities in the hypothalamic pathway of those with PWS results in. an absence of satiety, 
despite normal expression of appetite suppressing factors. By more completely understanding 
the abnormalities associated with PWS we will more completely understand the pathways of the 
hypothalamus and its role in body weight regulation and possibly other mechanisms influencing 
appetite. 
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POMC 
Another example of a genetic syndrome resulting in clinical obesity occurs from POMC 
gene deficiency. The POMC gene is a precursor protein for numerous peptides whose main 
function is to integrate hormonal signals from adipose tissue. POMC is synthesized in the 
arcuate nucleus of the hypothalamus when stimulated by Lep, the pituitary, the medulla and 
different peripheral tissues. POMC deficiency occurs as a result of a mutation of the POMC gene 
and ultimately results in a deficiency of its products including adrenocorticotropin and f>-lipotropin. 
ACTH's main function is to maintain adrenal cortex function and production of 
glucocorticoids. Additionally, when ACTH is produced in the hypothalamus, it is converted to a 
and 13 melanocyte-stimulating hormones. ACTH and a-MSH activate the brain melanocortin 
receptors 1, 2, 3, 4 and 5. The expression and action of the 5 MC-R's vary: MC1-R is expressed 
in melanocytes; MC2-R is expressed in the adrenal cortex and mediates the activity of ACTH; 
MC3 and 4-R are involved in energy homeostasis, specifically through the inhibition of energy 
intake and the activations of energy expenditure. Thus, disruption of the activity of the MC-R's, 
as through POMC deficiency, results in disruption of the melanocortin pathway. For example 
disrupting the activation of MC1, 2 and 5-R results in abnormal pigmentation, adrenal function 
and exocrine gland function. Likewise, disruption of MC3 and 4-R results in a disruption of 
energy homeostasis. In sum, consequences of POMC gene deficiency are a result of the 
absence of its derived peptides. 
Generalized POMC deficiency ultimately results in inactivation of the hypothalamus and 
irregulation of pigmentation and weight homeostasis via decreased energy expenditure and 
increased food intake. Major characteristic of POMC is red hair pigmentation, hyperphagia and 
early onset obesity that occurs within the first year of Hfe, despite adrenal insufficiency. However, 
the development of individuals with POMC deficiency is unaffected. From these observations it 
can be assumed that there is an important role for the central melanocortin system, including 
POMC and the brain MC-R's, in the maintenance of energy homeostasis. Abnormalities in the 
melanocortin pathway, such as through POMC deficiency, results in obesity. 
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It appears that with POMC deficiency, like PWS, the pathways for hyperphagia are 
inactive during the first few months of life and emerge later in early development. POMC children 
are born of normal weight and develop normally until the fifth month of life at which point patients 
are noted to become hyperphagic. Additionally, strict food restriction fails to prevent weight gain. 
Thus, it has been hypothesized that POMC signaling may affect metabolic rate (35,36). As in the 
instance of PWS, a more thorough understanding of the mechanisms of POMC deficiency will 
provide invaluable knowledge regarding weight gain and obesity, specifically in regards to 
hyperphagia and energy expenditure. 
MC4-R Mutation 
The most common monogenic cause of obesity in humans is a result of MC4-R 
mutations. About 4% of all cases of morbid adult obese are a result of MC4-R mutations. The 
MC4-R is a 7-transmembrane domain G protein-coupled receptor that is activated by the binding 
of a-MSH in the hypothalamus. Generation of an MC4-R knockout mouse has provided a great 
deal of information regarding MC4-R's roles. 
As discussed above, MC4-R is highly expressed in the hypothalamus and involved in the 
hypothalamus's regulation of weight. MC4-R's influence on food intake and energy homeostasis 
is a result of the peptides it produces, all of which come from POMC. Of all peptides, a-MSH 
seems to be the most relevant to feeding. Upon activation by a-MSH, MC4-R couples to a G 
protein and activates adenylyl cyclase, which catalyzes the formation of cyclic AMP from ATP. 
cAMP is involved in various signal transduction cascades. 
Experimenters have found that administration of an a-MSH analogue reduces food while 
administration of an a-MSH antagonist stimulates feeding, inducing hyperphagia and 
consequently obesity. An example of an MC4-R antagonist is agouti-related protein of which over 
expression results in hyperphagia and weight gain. Thus, the balance of AGRP and a-MSH 
influences either the stimulation or inhibition of eating. To even further confirm the essential 
functioning of a-MSH, and subsequently MC4-R, leptin has been found to stimulate the 
melanocortin pathway. This is consistent with the fact that both Lep and MC4-R inhibit feeding 
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and promote weight loss. Furthermore it has been found that blockage of MC4-R activity impairs 
leptins function. 
Individuals with an MC4-R mutation suffer from hyperphagia as early as 4 months of age, 
constantly seeking food and displaying distress when food is not provided. Additionally, those 
with a mutation in MC4-R also experience a marked increase in linear growth are 
hyperinsulinemic and hyperglycemic. However, unlike other obesity related diseases, pubertal 
development and reproductive function are unimpaired and individuals do not develop diabetes 
(37-40). 
THE METABOLISM OF LIPIDS: LIPOGENESIS AND ADIPOGENESIS 
As defined by the National Library of Medicine, adipose tissue is dense connective 
tissue, consisting primarily of adipocytes, in which fat is stored ( 41 ). The fat stored in the human 
body, specifically in the adipocytes of adipose tissue, is stored in the form of triglycerides. 
Adipose tissue accumulates in various sites around the body including the subcutaneous layer 
between the muscle and dermis, around the heart, kidney and other organs and is vital to daily 
body functions. There are two forms of adipose tissue, each with its own unique functions: white 
adipose tissue and brown adipose tissue. 
WAT is the predominant form of fat in developed humans, however during the neonatal 
period humans have significant depots of BAT. Triglycerides are stored in the adipocytes of WAT 
and during periods of dietary deficiency adipose tissue acts as a source of energy by releasing 
free fatty acids. WAT also has the ability to act as an endocrine organ, secreting hormones and 
cytokines that regulate various functions. Additionally, WAT protects joints and organs, regulates 
body temperature, stores vitamins, etc. (42) 
Contrary to the function of WAT as storage of energy, BAT dissipates energy in the form 
of heat through mitochondrial biogenesis. Additionally, while the lipid incorporated in the 
adipocytes of WAT is stored as a few large droplets, the lipid stored in BAT is stored as 
numerous minute droplets. BAT is characterized by its high content of mitochondria in which 
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uncoupling protein 1 is stored. When induced by the sympathetic nervous system, UCP1 
uncouples substrate oxidation and electron transport through the respiratory chain from ATP 
synthesis, thus generating heat. · BATs primary function is thermogenesis, providing a defense 
against cold and protection from obesity (43). 
WAT is essential to the normal functioning of the body. Thus, storage of triglycerides in 
adipocytes and the presence of WAT is critical to good health. Hence, the production of 
adipocytes and WAT has been the subject of substantial interest in hopes of isolating potential 
treatment options for syndromes resulting from too little or too much fat. Research to date has 
illustrated that adipose tissue is produced in two ways: lipogenesis and adipogenesis. Because 
of the importance of the development of adipose tissue and its implications in obesity, a more in . 
depth look into these two processes follows. 
Lipogenesis - The Production of Fatty Acids 
The body has a small capacity for the storage of carbohydrates and no ability to store 
protein. Thus, the storage of triglycerides in WAT is essential during periods of energy restriction 
in that it provides a constant source of energy: triglycerides are used as an energy source. 
During a fed state, triglycerides are stored in adipose tissue for later use (44). The triglycerides 
stored in WAT come from two main sources: diet and de novo synthesis or lipogenesis. 
Roughly 95 percent of fat consumed through diet is in the form of triglycerides. A 
triglyceride is a molecule consisting of three fatty acids (long chains of carbon atoms bound to 
each other with hydrogen's with a carboxyl group at one end) attached to a glycerol backbone. 
Triglycerides are· digested and eventually incorporated into chylomicrons at which point they are 
carried from the intestine into the lymphatic system where they are released into the bloodstream. 
Additionally triglycerides are packaged and transported in the form of VLDLs in the liver. 
Lipoprotein lipase hydrolyzes the triglycerides in the chylomicron and VLDL releasing individual 
free fatty acids, which are then transported into the adipocytes of adipose tissue. The fatty acids 
combine with coenzyme A, resulting in a thioester, which can then be re-esterified to a glycerol 
molecule forming a triglyceride. During periods of starvation, the stored triglycerides undergo 
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l ipolysis and are metabolized to glycerol and fatty acids for further oxidation. During the fed state, 
adipocytes reform the fatty acids into triglycerides and store the triglycerides for later use. 
De novo lipogenesis is the production of fat that occurs when total caloric consumption 
exceeds need. The main sites for de novo synthesis are the cytosol of adipose tissue and the 
liver. During the fed state (such as when consuming a high carbohydrate diet or when total 
caloric consumption exceeds the body's immediate requirements) glucose is converted to its 
storage form glycogen through glycogenesis. De novo lipogenesis occurs when glycogen stores 
are filled to capacity ultimately resulting in the production of palmitate. 
Phosphofructokinase is regulated allosterically and plays a major role in the regulation of 
glycolysis. Once glycogen stores reach capacity, the excess ATP and citrate inhibits 
phosphofructokinase production and stimulates the pentose phosphate pathway. Inhibition of 
PFK results in the channeling of glucose 6-phosphate to the pentose phosphate pathway where it 
is ultimately converted to glyceraldehydes 3-phosphate after undergoing a series of 
transformations. Glyceraldehyde 3-phosphate is then able to re-enter g lycolysis, bypassing the 
regulatory effects of phosphofructokinase, and is converted to pyruvate. 
After the conversion of glyceraldehyde 3-phosphate to pyruvate, pyruvate is transported 
via a carrier into the mitochondria. In the mitochondria, pyruvate is oxidized by pyruvate 
dehydrogenase to produce acetyl CoA that is then converted to citrate by citrate synthase. Citrate 
is then incorporated into the Krebs cycle. During periods of high energy consumption, the activity 
of the Krebs cycle is inhibited through the suppression of isocitrate dehydrogenase. 
Consequently, the reduction in the flow of metabolites through the Krebs cycle results in an 
accumulation of citrate in the mitochondria. The accumulating citrate then diffuses through the 
mitochondria into the cytosol via a citrate shuttle: the tricarboxylate carrier located in the inner 
mitochondrial membrane. 
Now cystolic, citrate is cleaved by citrate lyase forming acetyl CoA and oxaloacetate. 
Malonyl-CoA is synthesized from the carboxylation of acetyl-CoA via acetyl-CoA carboxylase. 
The fatty acid synthase complex then catalyzes the final steps of lipogenesis. The fatty acids 
synthase complex is a multienzyme complex that catalyzes 7 successive cycles ultimately 
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producing palmitate. The first cycle produces a 4-carbon acyl-ACP. The subsequent cycles act 
to build the fatty acid by the serial addition of 2 carbons to the growing fatty acid chain. After 
each addition of carbons, they are condensed, reduced, dehydrated and reduced again until, for 
example, the 16-C fatty acid palmitate has been formed. Once the acyl chain reaches 16 
carbons, the thioesterase domain of the fatty acid synthase complex cleaves the free fatty acid 
from the enzyme (45,46). 
As highlighted, lipogenesis is the process by which fat is produced. The lipogenesis 
process relies on the presence of several critical transcripts. To date, little is known about how 
transcript levels might alter lipogenesis. Nonetheless, the presence or absence of these 
transcripts may be important determinants of hyperphagia and hyperinsulinemia and may 
ultimately contribute to obesity. The following section examines 10 specific transcripts that are 
thought to play critical roles in lipogenesis: fatty acid synthase, lipoprotein lipase, malic enzyme, 
transketolase, glycerol 3-phosphate acyltransferase, stearoyl CoA desaturase 1, farnesyl 
diphosphate synthase and leptin. 
Transcripts of Special Interest 
Because increased lipogenesis activity results in adiposity, the study of the transcripts 
that under gird lipogenesis may prove fruitful in providing new insight into the problem of obesity. 
The following discussion examines the role that 10 key transcripts play in lipogenesis. One of the 
transcripts appear critical to energy homeostasis and seven are involved in lipogenesis and 
cholesterol synthesis. The following discussion examines the lipogenic enzymes first and then 
shifts attention to the transcripts involved in energy regulation. In short, the following transcripts 
are discussed below: fatty acid synthase, lipoprotein lipase, malic enzyme, transketolase, glycerol 
3-phosphate acyltransferase, stearoyl CoA desaturase 1, farnesyl diphosphate synthase and 
leptin. 
Fatty Acid Synthase 
FAS is a multifunctional enzyme expressed mostly in the lipogenic tissues liver and 
adipose tissue. Fatty acid synthase primarily synthesizes the long-chain saturated fatty acid 
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palmitate (16 carbon fatty acid), but also stearate (18 carbon fatty acid) and myristate (14 carbon 
fatty acid), from acetyl-CoA, malonyl-CoA and NADPH. These long-chain fatty acids can then be 
used for the synthesis of triglycerides and phospholipids. 
High insulin levels (often resulting from a high carbohydrate diet) stimulate FAS 
synthesis. Additionally, high FAS levels are correlated with high carbohydrate, low-fat diets. 
Conversely, FAS expression is inhibited by glucagon (a hormone secreted in response to the 
fasted state) and consumption of polyunsaturated fatty acids, amino acids, and sterols (47). 
Lipoprotein Lipase 
Also discussed earlier, Lpl is responsible for the release of free fatty acids from 
triglycerides. Increased levels of insulin, such as those occurring during the fed state, stimulates 
the transcription and synthesis of l ipoprotein l ipase in adipose tissue. Lpl is then translocated to 
the walls of blood capillaries at which point it attaches to the endothelium where it can hydrolyze 
triglycerides in chylomicrons and VLDLs into free fatty acids. Fatty acids can then be 
incorporated into white adipose tissue or oxidized as fuel, and glycerol. Thus, lipoprotein l ipase 
assists in the clearance of chylomicrons and VLDL from the blood, protecting the body from 
hyperlipidemia, as well as the accumulation of triglycerides in WAT (48). 
Transketolase 
The flux of glucose 6-phosphate into the pentose phosphate pathway is stimulated once 
excess glucose has surpassed levels needed for glycogen storage. Transketolase is a thiamin 
dependent enzyme linking glycolysis with the pentose phosphate pathway by catalyzing reactions 
in the non-oxidative branch of the pathway. Specifically, Tkt catalyzes the conversion of xylulose 
5-phosphate and ribose 5-phosphate to glyceraldehyde 3-phosphate and sedoheptulose ?­
phosphate by transferring a two-carbon unit from a ketose to an aldose. With the help of 
transaldolase, transketolase can ultimately form fructose 6-phosphate and erythrose 4-phosphate 
from glyceraldehyde 3-phosphate and sedoheptuloase ?-phosphate (49). The pentose 
phosphate pathway produces NADPH, a necessary constituent of l ipogenesis and cholesterol 
synthesis. Tkt activity is upregulated under the influx of glucose 6-phosphate and the need for 
NADPH for fatty acid synthesis. 
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Malic Enzyme 
Cystolic malic enzyme catalyzes the reversible oxidative decarboxylation of malate 
forming pyruvate, CO2 and NADPH. Specifically, citrate formed in the Krebs cycle is translocated 
from the mitochondrion to the cytosol via the tricarboxylate carrier. When under the presence of 
CoA and ATP, citrate is cleaved into acetyl CoA and oxaloacetate. Oxaloacetate can then be 
reduced to malate. Finally, malate undergoes oxidative decarboxylation by NADP+ and ME1, 
forming acetyl CoA and NADPH (50). It has been found that fatty acid synthesis requires 0.62 
µmole of NADPH per minute per gram of adipose tissue. The pentose phosphate pathway 
provides 0.39 µmole of NADPH per minute per gram of adipose tissue leaving a need for 0.23 
µmole of NADPH (51). Pyruvate carboxylase activity runs at about 0.22 µmole/g of adipose 
tissue per minute, providing a sufficient amount of oxaloacetate that ultimately can produce the 
required 0.23 µmole of NADPH per gram of adipose tissue per minute needed for fatty acid 
synthesis through malic enzymes action (52). Thus, it can be assumed that during lipogenesis 
malic enzyme activity would be induced dramatically, generating NADPH to support lipogenesis. 
Glycerol 3-phosphate acy/transferase 
Mitochondrial Gpam catalyzes the initial step in triglycerides and phospholipid synthesis. 
Similar to FAS, Gpam is expressed primarily in liver and adipose tissue. The synthesis of 
glycerophospholipids begins with the acylation of Gpam with fatty acyl-CoA, generating 
monoacylglycerol 3-phosphate. Monoacylglycerol 3-phosphate is then acylated further, forming 
triacylglycerols to be used for storage in adipose tissue. 
Like other lipogenic enzymes, Gpam mRNA is stimulated by insulin during 
fasting/refeeding and high carbohydrate diets. Additionally, Gpam is predicted to play a role in 
the regulation of cellular triacylglycerol and phospholipid levels. Mice deficient in glycerol 3-
phosphate acyltransferase experience decreased fat pad mass, body weight, hepatic and plasma 
triacylglycerol content and VLDL triacylglycerol secretion (53,54). 
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Stearoyl CoA desaturase 1 
Scd1 is a lipogenic enzyme that catalyzes the delta-9-cis desaturation of fatty acids and 
forms the monounsaturated fatty acids palmitoleate and oleate. In detail, stearoyl CoA 
desaturase 1 removes a hydrogen atom at the delta 9 position and then an additional hydrogen 
atom at the delta 10 position of the fatty acid. Thus, a double bond is formed between carbons 
number 9 and 1 0  in the cis position. 
Insulin has been found to upregulate the expression of Scd 1 ,  while leptin and glucagon 
inhibit expression. Additionally, while glucose and fructose upregulate activity, polyunsaturated 
fatty acids have been found to down regulate activity. Recent studies have demonstrated that 
inhibition of Scd1 results in decreased levels of cholesterol, triglycerides, and monounsaturated 
fatty acids. Additionally, SCD1 deficient mice are resistant to diet induced weight gain and 
experience increases in 13-oxidation, metabolic rates, and down-regulation of lipogenic enzymes. 
Consequently, deficiency in Scd1 facilitates loss of fat mass and body weight (55,56). 
Farnesyl diphosphate synthase 
Farnesyl diphosphate synthase is a peroxisomal enzyme involved in the synthesis of 
cholesterol. Specifically, Fdps catalyzes the formation of famesyl diphosphate from isopentenyl 
diphosphate and dimethylallyl diphosphate. Farnesyl diphosphate is a precursor for many 
molecules including bile acids, steroid hormones and cholesterol. Transcription of Fdps is 
regulated by sterols and coordinately regulated with HMG-CoA reductase and HMG-CoA 
synthase (57) . 
Leptin 
Leptin is a hormone secreted from adipose tissue involved in energy homeostasis. 
Leptin is secreted in direct proportion to white adipose tissue in the fed state. However, during 
periods of fasting leptin gene expression diminishes markedly. In  the fed state leptin is 
expressed via receptors that results in the inhibition of feeding and increase of thermogenesis 
(58). 
In the hypothalamus, Lep binds to two distinct sets of neurons. One set of neurons 
influenced by leptin is the orexigenic neuropeptides NPY and AGRP. Lep has been found to 
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suppress expression of these neuropeptides. The other set of neurons of which leptin induces 
expression of is the anorexigenic a-MSH and CART. Thus, the influence of leptin on the 
induction of feeding results from the balance of orexigenic to anorexigenic neuropeptides. In 
rodent models, administration of leptin has been found to reduce food intake (59). A more 
explanatory focus of leptin occurs in the following discussion of the rodent model. 
Adipogenesis - The Production of Adipose Tissue 
Adipogenesis, or adipose cell differentiation, is the conversion of preadipocytes into 
adipocytes containing lipid. Adipogenesis occurs as a result of normal cell turnover and a 
requirement for additional fat mass due to excess total caloric consumption, requires a balance 
between the activation and repression of adipocyte-specific genes. In order for adipogenesis to 
occur a proliferating network of capillaries in an area of loose connective tissue must be present. 
Adipocytes develop from mesenchymal stem cells in two major steps (figure 1 ). In the 
first step differentiation occurs - the stem cells are dedicated to the production of adipocytes, 
rather than in the production of muscle or bone, resulting in cells with fibroblast-like morphology 
or "pre-adipocytes. " The adipocyte differentiation process directly influences the total amount of 
adipocytes produced. In the second step the pre-adipocytes fully differentiate through mitogenic 
and adipogenic signal, resulting in the progressive acquisition of the morphological and biological 
characteristics of the mature adipocyte. Some suggest that insulin/insulin like growth factor 1 
(IGF-1 ), glucocorticoid and cyclic AMP signaling pathways play roles in the differentiation process 
(60). 
After cycles of DNA replication and expansion of cells the adipocyte doubles in size and 
transforms into a spherical shape. Additionally, changes occur in the composition of the 
adipocyte that are required for the development of the mature adipocyte. Degradation of the 
extracellular matrix occurs and the presence of cytoskeletal components changes thus resulting 
in alterations in shape, lipid accumulation and adipocyte-specific gene expression. The 
progressive acquisition of the adipocyte phenotype corresponds with changes in expression of 
more than 2000 genes. Additionally, it seems the transition in ceil size and composition may be 
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Figure 1 .  Adipogenesis. Adipocytes develop from mesenchymal stem cells in two steps: 
differentiation and adipocyte development In  differentiation occurs the stem cells are dedicated 
to the production of adipocytes and become "pre-adipocytes." In the second step the pre­
adipocytes fully differentiate ultimately resulting in the morphological and biological characteristics 
of the mature adipocyte. 
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a point of adipogenesis regulation possibly through the promotion of adipogenic transcription 
factors (42,60,61 ). 
Transcriptional Regulation of the Differentiation Process 
Adipose cell differentiation is influenced by various methods of regulation including 
nutrient stimuli, hormonal regulation and regulation at the level of transcription. Peroxisome 
proliferator activated receptor gamma, CCM T /enhancer binding proteins and adipocyte 
determination and differentiation factor 1/sterol regulatory element binding protein 1 are families 
of transcription factors that play key roles in the regulation of adipogenesis as well as the 
development of the mature adipocyte. 
PPARy 
PPARy, found primarily in WAT, is a member of the nuclear hormone receptor 
superfamily is responsible for the regulation of gene transcription. PPARy is hypothesized to be a 
key player in the adipocyte differentiation process because PPARy expression is induced prior to 
the activation of most adipogenic genes. Expression of PPARy seems to induce growth arrest 
and initiate adipogenesis in fibroblasts. On the other hand, studies regarding the loss of PPARy 
function have demonstrated that PPARy is necessary to promote fat cell differentiation and 
antagonists that phosphorylate PPARy, such as MAP kinase, lead to its inactivation and 
subsequent suppression of differentiation. Additionally, natural ligands to PPARy such as TZDs 
and prostaglandins have been found to induce adipogenesis (62). A more detailed discussion of 
PPARy occurs below. 
CIEBP 
C/EBP's belong to the basic-leucine zipper class of transcription factors and were the 
first transcripts that was found to play a pivotal role in adipocyte differentiation. C/EBPa, 13 and o 
are expressed at specific pointes during adipogenesis. C/EBPl3 and d are present in 
preadipocytes and their expression increases during early differentiation (60). C/EBP13 and d 
influence adipocyte differentiation through their induction of PPARy and are induced by 
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glucocorticoids, cAMP and insulin. C/EBPa is expressed late in differentiation ,  prior to the 
transcription of adipocyte-specific genes such as Scd 1 ,  leptin and the insulin receptor. C/EBPa 
has been found to sustain the elevated levels of PPARy (influenced by C/EBPl3 and 8). Loss of 
function studies have also found that C/EBPl3 and 8 induce determination and differentiation 
whereas overexpression of C/EBPa induces preadipocyte differentiation into mature adipocytes 
(62). 
ADD1/SREBP1 
ADD1 /SREBP1 is also believed to be a key determinant of adipocyte d ifferentiation and 
lipogenesis, however to a lesser extent than PPARy and the C/EBPs. ADD1 /SREBP1 mRNA 
levels are increased during preadipocyte differentiation, suggesting its role in the differentiation 
process. Additionally, coexpression of ADD1 /SREBP1 increases PPARy expression ,  
independent of ligand activation ,  possibly through its inductions of endogenous ligands for 
PPARy. Though little is understood, SREBP1s induction of PPARy is believed to be the 
mechanism underlying SREBP1 s actions (60,63) . 
Hormonal Regulation of the Differentiation Process 
Various hormones have been found to induce differentiation as well. I nsulin has been 
found to increase the percentage of cells that differentiate. It also increases the amount of lipid 
accumulation in adipocytes through its cross activation of the IGF-1 receptor, though the exact 
mechanisms are not clear. Both insulin and IGF-1 stimulate ras, which in turn induces 
adipogenesis. On the other hand,  reductions in adipocyte differentiation appears positively 
related to reductions in ras expression. Glucocorticoids have also been found to induce 
differentiation through its induction of C/EBP8. Lastly , growth hormone has been found to induce 
adipocyte differentiation, however very little is understood regarding the mechanisms. 
Conversely, cytokines such as TNF-a and growth factors such as PDGF are responsible 
for the suppression of differentiation as well as the dedifferentiation of mature fat cells. It is 
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hypothesized differentiation is mediated by MAP kinase. MAP kinase phosphorylates PPARy, 
thus inhibiting its adipogenic activity and the resulting differentiation it promotes (42,60). 
Transcriptional Regulators of Special Interest 
In addition to the previously discusseq transcripts, PPARy and insulin induced gene 1 are 
of special interest to this research. Of particular interest is .the role they play in differentiation and 
the regulation of gene expression involved in glucose utilization and lipogenesis. 
PPARy 
The binding of ligands to PPARy results in the transcription of various target genes 
through the release of corepressors and recruitment of coactivators. With regards to 
adipogenesis, PPARy manipulates the influx and efflux of fatty acids in adipose tissue through the 
activation and suppression of various genes. PPARy stimulates LPL in adipocytes resulting in the 
generation of FFA from circulating lipoproteins. The uptake of FFAs is increased by PPARy 
stimulation of fatty acid transporters fatty acid transport protein a molecule that facilitates entry, 
acylation and esterification of FFAs in adipocytes. FFA efflux is reduced by PPARy induction of 
glycerol-3-phosphate, phosphoenolpyruvate carboxykinase and glycerol kinase, all of which 
promote the production and storage of triglycerides. These actions of PPARy ultimately result in 
increased uptake and reductions in total serum FFA levels. Additionally, ectopic expression of 
PPARy has been found to induce the differentiation of fibroblastic cells into preadipocytes. Thus, 
PPARy activity influences the composition and number of adipocytes as well as circulating fatty 
acids. 
Unsaturated fatty acids such as oleate and linoleate, arachidonic acids, prostaglandins, 
and members of the thiazolidinediones family have all been found to activate PPARy. PPARy 
activation has been found to play a role in adipogenesis as well in mediating the insulin­
sensitizing action of TZDs. TZDs are synthetic compounds developed as insulin sensitizers for 
the treatment of insulin resistance in patients with NIDDM through regulation of hyperglycemia, 
hyperinsulinemia, and hyperlipidemia. It was later discovered the target of TZDs was PPARy -
TZD is ligand of adipocyte-specific PPARy. TZDs antidiabetic affects are primarily elicited by 
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their improvement of muscle insulin sensitivity. One hypothesis regarding the mechanisms of 
TZDs, and subsequently PPARy, is related to its impact on fatty acids. Activation of PPARy may 
result in channeling fatty acids into adipose tissue, thus decreasing plasma concentration levels. 
The reduction of circulating fatty acids leads to increased insulin sensitivity in muscle tissue 
(64,63). 
Insulin induced gene 1 
lnsig1 , a protein located in the endoplasmic reticulum, is one of the most highly induced 
genes in liver cells (65). lnsig1, whose expression increases in response to a insulin levels, binds 
to the sterol-sensing domain of sterol regulatory element-binding protein cleavage-activating 
protein when in the presence of sterols (66). On the other hand, when cells are low in sterol's 
SCAP binds to SREBP and escorts SREBP from the ER to the golgi complex enabling SREBPs 
stimulation of cholesterol synthesis. lnsig1s binding with SCAP inhibits the movement of the 
SCAP/SREBP complex from the ER to the golgi complex thus, inhibiting the activation of SREBP 
and consequently cholesterol synthesis. The greater the expression of lnsig1, the greater the 
influence on cholesterol homeostasis (67). Additionally, the inhibition of SREBP1-c specifically 
was found to result in reduced expression of SREBP1-c target lipogenic enzymes, such as Scd1 
and FAS, arguing insig1s antilipogenic action {68). 
Sever et al. found that lnsig1 is also capable of regulating cholesterol through its actions 
on HMG CoA reductase. In a similar manner as SCAP, lnsig1 binds to the sterol-sensing 
domains of HMG CoA reductase stimulating accelerated degradation of HMG CoA reductase and 
inhibiting cholesterol synthesis. Additionally, SCAP and HMG CoA reductase have been found to 
compete for the same binding site of lnsig1 ,  a mechanism that may play a crucial role in 
cholesterol homeostasis {69). 
Lastly, it has also been observed that over expression of lnsig1 inhibits the differentiation 
of preadipocytes and limits triglyceride synthesis and accumulation in adipocytes. In mice, lnsig1 
mRNA rose in response to the feeding of a high-fat diet. On the other hand, insig1 mRNA 
decreased in mice in response to a low-fat diet. The upregulation observed in lnsig1 mRNA is 
believed to be a result of the increased fat mass that accompanies feeding of a high fat diet. On 
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the other hand, lnsig1 expression was downregulated in response to decreased fat mass ocurring 
as a result of the low fat diet (66). 
THE RODENT MODEL 
The rodent model has proven to be invaluable in its role in human obesity research. The 
genetics of obesity is a complicated syndrome that is a result of various mechanisms, some of 
which occur simultaneously. Insight into various obesity related candidate genes have been 
identified through use of animal models. Specifically, use of rodents has provided invaluable 
information regarding the role of leptin, NPY, CRH , MC3, etc. all of which are directly related to 
the development of obesity. The following paragraphs will go into detail regarding the animal 
model, the Zucker fatty (fa/fa) rat, employed in this research effort. 
The Zucker fatty (fa/fa) Rat 
The fatty rat, a rat homolog of the db/db mouse displaying the same phenotype, is used 
as a model of early onset obesity. The fatty rat was discovered by Theodore and Lois Zucker in 
1 961 through research on the susceptibility for the inheritance of obesity. A gene was found that 
was responsible for the development of obesity and was subsequently labeled the "fatty gene" 
(fa). The fa mutation was mapped to rat chromosome 5, further arguing that the fa and db 
mutation are homologous genes (70). 
The fatty rat inherits the fa gene as an autosomal recessive mutation. Because the fa 
gene is inherited, the mutation is present at the time of conception and its influence occurs during 
the early stages of life. The mutation associated with the fa-gene encodes for a shortened leptin 
receptor protein that cannot interact with leptin, thus the leptin receptors do not function properly. 
The mutant leptin receptor appears to influence the hypothalamus' ability to regulate feelings of 
satiety (71 ). 
The fa gene acts on leptin receptors impacting the hypothalamus. Leptin is a hormone 
whose primary physiological function is its anorectic effects. The fatty rat inherits an amino acid 
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substitution at position 269 of the leptin receptor protein sequence. Specifically, the leptin 
receptors of those with the fa mutation contain a mutation at nucleotide position 880 resulting in a 
conversion of adenine to cytosine. This causes amino acid 269, glutamine, to change to praline 
in the extracellular domain (72). Thus, though the fatty rat experiences high levels of circulating 
leptin, the mutant leptin receptor is not capable of binding the leptin for transport across the 
blood-brain barrier to the hypothalamus. Deficiencies in the hypothalamus ultimately result in 
reduced sensations of satiety and thus, hyperphagia (73). Fatty rats grossly overeat to the point 
of obesity. 
Fatty rats are hyperphagic, obese, infertile and suffer from hyperinsulinemia, however 
blood glucose levels are normal. Fatty rats also suffer from hypertriglyceridemia due to increased 
production of VLDL by the liver. Fatty rats experience increases in adipocyte size and number 
with subcutaneous fat pads showing the largest increase in fat cells compared to nonmutants. 
Additionally, leptin secretion occurs in proportion to fat mass but is ineffective in regards to its 
anorectic effects due to the defect in the leptin receptor gene. The phenotypic characteristics of 
fatty rats are comparable to obese rats with hypothalamic dysfunction. 
Interestingly, though the weight gain in the fatty rat is significant, rat pups with the fa 
mutation are indistinguishable from littermates until 23 days of age. Truett et al found that when 
rat pups were left with their dam until 28 days of age (rather than the customary 21 days of age) 
the fatty rat experiences a developmental change that is manifested by 23 days of age. Fatty rats 
weigh significantly more than lean littermates on day 23, stomach contents and liver weight are 
increased and plasma insulin levels are elevated , thus displaying the phenotypic characteristics 
of the fa gene mutation. Additionally, this genotype effect is apparent through visual inspection of 
their bellies at 24 days of age which protrude do to the onset of hyperphagia. The dramatic 
increase in growth rate at 23 days of age is attributed to the decreased responsiveness to leptin 
after which the fatty rat develops hyperphagia and hyperinsulinemia. The authors concluded that 
a change occurs in the genes associated with growth and obesity during the 4th week of life 
during which the activation of a "developmental switch" takes place resulting in hyperphagia (74). 
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The observation that the onset of hyperphagia in the fatty rat occurs after the third week 
of life leads one to believe the pathways that mediate the onset of hyperphagia are 
underdeveloped or inactive, later emerging during the fourth week of life. Because the 
development of hyperphagia occurs during the first few weeks of life, the fatty rat is a useful 
animal model with regards to the early development of obesity. The following paragraphs will 
discuss the influence of the fa gene in those possessing the mutation with regards to leptin and 
the leptin receptor. The focus will then shift to the characteristics of the Zucker fatty rat including 
hyperphagia, the implications of weaning and thermogenesis. 
Leptin and Leptin Receptors 
- The actions of leptin were first discovered through studies of ob/ob and db/db mice, 
which suffered hyperphagia, early onset obesity and decreased energy expenditure. It was found 
that parabiosis of ob/ob mice and wildtype mice suppressed weight gain in mutants. 
Alternatively, parabiosis of db/db mice and wildtype mice resulted in hypophagia in wildtype mice. 
The observation led researchers to believe that ob/ob mice secrete a factor db/db mice respond 
to - this factor was later named leptin. 
Leptin, a product of the ob gene, is a hormone synthesized and excreted predominantly 
in white adipose tissue. Expression of leptin is proportional to energy stores and is responsible 
for anorectic effects. Additionally, leptin levels fluctuate in response to fasting and feeding: leptin 
levels rise during the fed state and fall during the fasted state. Leptin exerts its effects on energy 
balance through its actions on the hypothalamic region of the brain. Expression of leptin results 
in a reduction in food intake, increases in energy expenditure and increase in physical activity. 
As might be assumed, disruption of leptin's actions, as those that occur through receptor 
mutations, result in hyperphagia, increased adiposity, decreased energy expenditure, etc. 
Recent research has also found leptin to have an effect on the regulation of lipid metabolism and 
protection from lipotoxicity (75). 
The regulation of leptin appears to be mediated by insulin - leptin expression increases 
after insulin levels peak following a meal. On the other hand, leptin expression decreases during 
periods of low insulin levels, such as while fasting. Glucocorticoids also mediate leptin's actions 
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through stimulation of synthesis in adipo<?ytes. Additional ly, acute infections and cytokines 
increase leptin expression in adipose tissue while testosterone and exposure to cold decrease 
leptin expression. 
Leptin-sensitive neurons are found in the hypothalamus in nuclei that express 
neuropeptides (such as NPY, AGRP, POMC and CART) that are involved in the regulation of 
energy balance (76). Leptin interacts with its receptor OB-R, a member of the cytokine receptor 
superfamily. There are five receptor isoforms: OB-Ra, OB-Rb, OB-Re, OB-Rd, OB-Re, OB-Rf. 
However the long isoform leptin receptor is believed to be the functioning receptor. OB-Rb is 
highly expressed in the hypothalamus. The principal signaling transduction pathway of leptin is 
the Jak/STAT pathway. Because OB-R do not have enzymatic domains they must bind with 
cytoplasmic tyrosine kinases of the janus kinase family. In brief, circulating leptin binds to the 
leptin receptor activating Jak kinases. Jak kinases then phosphorylate other janus kinases as 
well as specific tyrosine residues of the receptor (77). Phosphorylation of the tyrosine residues 
provides docking stations downstream for ST AT proteins. ST AT proteins eventually trans locate 
to the nucleus and act as transcription factors by binding specific response elements in the 
promoter of their target genes. 
Although OB-Rb is the functioning receptor, other receptor isoforms may stil l  be 
necessary for mediating leptin's biological effects. For example OB-Ra is highly expressed in the 
brain and blood-brain barrier. Additionally, the fatty rat lacks OB-Ra and experiences reduced 
levels of leptin in the cerebrospinal fluid. As such, it has led researcher to suggest that OB-Ra 
may be involved in the transport of leptin across the blood brain barrier to reach the 
hypothalamus, thereby validating the role of the short form leptin receptor in leptin transport to the 
hypothalamus (58,59,78). 
Hyperphagia 
As discussed earlier, fatty rats develop hyperphagia resulting in severe weight gain. 
Several studies have focused on diet consumption, timing of the onset of hyperphagia and weight 
gain. Despite the efforts, the findings are largely ambiguous and contradictory in nature. For the 
most part, the research lacks a definitive understanding of the relationship between pathway 
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activities and hyperphagic onset. Moreover, researchers have yet to determine the nature of how 
diet composition influences hyperphagic behavior. Much of the lack of definitive findings is further 
complicated by the lack of generalization deriving from the use of multiple research 
methodologies. 
As a case in point, Turkenkopf, Maggio and Greenwood found that while all fatty rats 
became hyperphagic, those weaned at day 1 6  to a standard chow diet (high in carbohydrate) 
experienced lower overall body weight and fat pad mass compared to those weaned to a high fat 
diet (79). Yet, Ramirez and Friedman found that fatty rats weight gain was associated with a diet 
rich in carbohydrates (80). Others suggest that a high fat diet influences the onset, duration and 
magnitude of hyperphagia in developing obesity (81 ). 
With regards to onset of hyperphagia, Kowalski et al attempted to determine the period 
during which hyperphagia emerges. To do this, researchers examined the ingestion of 
preweanling rats independent of the dam. They found that hyperphagia to emerged between day 
9 and 1 2  of life, with significant consumption of food occurring at day 1 2  (71 ). However, Truett et 
al found a significant increase in daily gain,  stomach contents, liver weight and plasma insulin 
levels occurring at 23 days of age. Additionally Bazin and Lavau reported no difference in body 
weight between fatty rats and wildtypes at 22 days of age, but a significant difference by 30 (82). 
Despite these conflicting reports, one finding appears to consistently surface -- fatty rats 
develop hyperphagia after the first week and before the fourth week of life. Thus, research 
indicates that the pathways influencing hyperphagia are not fully developed in the rat pup in the 
first week of life. The pathways mediating hyperphagic behavior appear to exhibit a delayed 
onset with manifestation occurring later in life. 
Little is known about the physiological changes that occur early in development that 
trigger the manifestation of hyperphagia. Researchers have found that lipogenic enzyme activity 
of adipose tissue is significantly increased in fatty pups, prior to the onset of hyperphagia. Bazin 
et al found a 50% increase in the activity of adipose lipogenic enzymes, including FAS, Me1 , CCE 
and G6PDH, in fatty rats at 9 days of age followed by a doubling of adipose mass by 1 7  days of 
age. An increase in lipogenic enzyme expression in the liver did not occur. The authors asserted 
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these findings are in accordance with the "pull" theory of obesity first recognized by Cleary, 
Vasselli and Greenwood (82,83). This theory asserts that the increase in adipocyte lipoprotein 
lipase activity in the early development of fatty rats results in an increase in the funneling of 
nutrients into the adipose tissue, leading to hyperphagia. It was concluded that the primary 
alteration in the fatty rat would be an increase in lipogenic enzyme activities in adipose tissue, 
channeling ketone bodies, glucose and amino acids into adipose tissue. Apparently, low levels of 
circulating hunger-suppressor substrates increases the drive to eat in fatty pups. Hyperphagia 
coupled with hyperinsulinemia appears to stimulate hyperlipogenesis in the liver and increased 
lipogenic enzyme activities in adipose tissue. However, it was also found that lipogenic enzyme 
activity in adipose tissue continued to increase after the onset of hyperphagia. Thus, it seems 
that though increased expression of FAS, CCE, Me1 and G6PDH are perhaps correlated with 
hyperphagia they do not cause the onset of hyperphagia. 
Lastly, in a study conducted by Cheverud et al (1996), the set of genes that regulate 
growth during the first three weeks of life differs from the set of genes that regulate growth in later 
life. Thus, the timing of developmental changes are in fact regulated by different sets of genes 
(84). Overall, the findings tend to suggest that the various pathways that mediate hyperphagia 
are not completely developed within the first weeks of life. A more in depth understanding of this 
animal model will provide valuable information and a more thorough understanding of the specific 
role the pathways play in the development of hyperphagia and obesity. 
Weaning 
Impact of weaning on rat pups must be considered when assessing onset of hyperphagia 
and subsequent weight gain. During the first two weeks of life, rat pups consume dam's milk 
exclusively. Dam's milk is high in fat (68%) and low in carbohydrate. Additionally, suckling does 
not appear to be influenced by circadian rhythms, which are oftentimes important in determining 
the sleeping and feeding pattern in animals. After about two weeks of life, rat pups begin to 
consume small quantities of rat chow in addition to dam's milk. Standard chow diets are high in 
carbohydrate (60%) and low in fat. By the end of the fourth week of life pups are weaned and 
their diet is exclusive to rodent chow. Thus, the diet of rat pups changes during weaning from 
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high fat, low carbohydrate to low fat, high carbohydrate. It has been noted that hyperphagia 
occurs during the weaning transition when pups experience a marked shift in their macronutrient 
intake. It is believed that this shift from the high fat dam's milk to a standard high carbohydrate 
chow diet could contribute to the onset of hyperphagia at this age (85,86). 
As discussed above, rats are dependent on dam's milk until roughly the 4th week of life. 
When left with the dam to wean naturally and gradually, rat pups can nurse up to 5 weeks of age. 
Common practice in research laboratories includes the abrupt weaning of rat pups from their dam 
at 3 weeks of age. The abrupt weaning transition is required to prevent consumption of dam's 
milk from contaminating consumption findings. The premature weaning results in both immediate 
and delayed effects. 
With respect to the gastrointestinal tract, the increase in production of enzymes that 
digest carbohydrates (such as pancreatic amylase and intestinal sucrase) occurs gradually in 
pups left to wean on their own. However when weaned early, a large increase in these enzymes 
occurs instantaneously, via adrenal stimulation. Another consequence of premature weaning is 
the induction of stress responses. Rat pups loose a significant amount of weight when weaned 
prematurely, which can take up to 4 days to recover. Moreover, premature weaning during this 
crucial time period results is known to lead to stunted growth. Finally, there appears to be a 
relationship between weight loss after premature weaning and the immaturity of food intake 
mechanisms and digestive processes later in life (86,87). In all, the switch from a high fat diet to 
a high carbohydrate diet is accompanied by various developmental changes including an 
induction of enzymes for carbohydrate metabolism. These factors may influence the 
development of hyperphagia, hyperinsulinemia and lipogenesis in the fatty rat. Thus, weaning 
pups prematurely at three weeks of age may render current findings regarding the onset of 
hyperphagia suspect, if not moot. 
Thermogenesis 
Rat pups are dependent on their dam for maintenance of body temperature through the 
second week of life. The removal of the dam prematurely has been found to delay the maturation 
of the thermoregulatory functions of the pups (86). Additionally, it has been found that fatty rats 
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experience a reduction in energy expenditure before the onset of hyperphagia. Apparently, 
brown adipose tissue plays a role in both heat dissipation and thermogenesis. The 
hypothalamus, in concert with the sympathetic nervous system, controls thermogenesis of BAT in 
response to factors such as the environment and diet. Effective thermogenesis of BAT is 
associated with leanness and decreased metabolic efficiency while defective thermogenesis is 
associated with increased metabolic efficiency resulting in weight gain. The Zucker fatty rat 
experiences defective BAT in response to diet. However, environment induced thermogenesis 
functions normally. BAT possesses the ability to uncouple protons, thus activating the 13-
oxidation pathway. This results in non-shivering thermogenesis. 
Preobese · fatty rats often maintain a lower body temperature that lean littermates 
resulting in higher amounts of adipose mass accumulation. However, researches have found that 
when fatty rats are artificially reared in a neutral thermal environment their body-fat is 
indistinguishable from littermates before the onset of hyperphagia (88,89). Fatty rats, when 
compared to their wildtype littermates, tend to experience a reduced rate of thermogenesis, which 
apparently influences weight gain before the onset of hyperphagia. Hence, the diminished rate of 
energy expenditure may prove to be a significant contributor to the early development of obesity 
in the fatty rat. 
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CHAPTER 2. TRANSCRIPTIONAL CHANGES IN ADIPOSE TISSUE 
INTRODUCTION 
The Zucker fatty (fa/fa) rat is an animal model of obesity that has provided a means to 
study genetics and its role in the development of obesity (30). The fatty rat inherits a defective 
leptin receptor which results in impaired leptin signaling (71 ). Fatty rats grow at the same rate as 
their lean littermates for their first 22 days of age -- then suddenly begin to grow at a much higher 
rate. This sudden increase in growth corresponds with the emergence of robust hyperphagia rat 
and leads to overt obesity within days. By 24 days of age fatty rats are visibly distinguishable 
from their lean littermates by the distension of their bellies (74). 
The fact that the onset of hyperphagia occurs at a specific age, when animals are without 
any environmental changes, suggests that a developmentally regulated mechanism may 
determine the timing of the onset of hyperphagia. For example, previous work found that fatty 
rats are insulin resistant prior to the onset of hyperphagia and insulin sensitive afterwards (90). 
The inc;rease in insulin sensitivity may be attributable to an increase in lipogenesis, which enables 
glucose to be cleared from circulation. The increase in lipogenesis may in turn be related to a 
developmental increase in expression of PPARy (90), a nuclear receptor that regulates the 
expression of lipogenic enzymes. 
The rapid increase in growth of adipose tissue after the onset of hyperphagia is likely to 
alter the sets of gene regulating adipose tissue growth and metabolism. The objective of the 
project was to identify the sets of genes differentially expressed between wildtypes and fatties 
before and after the onset of hyperphagia. Transcripts that are differentially expressed after the 
onset of hyperphagia will include those that are primarily affected by reduced leptin signaling and 
those secondarily affected by hyperphagia and the physiological responses that accompany it, 
such as hyperinsulinemia. Transcripts that are differentially expressed prior to the onset of 
hyperphagia will include the secondary responders. I nstead, this set of transcripts will include 
those primarily affected by reduced leptin signaling, increased energy efficiency, increased 
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adipose mass and adipocyte development. This analysis will identify which pathways are active 
under these two physiological conditions and mighty identify pathways that are critical for the 
development of hyperphagia. 
MATERIALS AND METHODS 
Experimental Design 
We have previously demonstrated that hyperphagia emerges at 23 days of age in the 
fatty rat. An experiment was designed to generate inguinal adipose tissue samples for RNA 
extraction at two points in development, one shortly before the onset of hyperphagia (20 days of 
age) and one shortly after the onset of hyperphagia (24 days of age). Other data were collected 
to verify that animals were not hyperphagic at the first age, but were hyperphagic at the second 
age. 
Animals 
Animals were produced in the principal investigator's colony of inbred Zucker-fa rats. 
They were housed in plastic breeder boxes with wood shavings as bedding and ad libitum access 
to Teklad 8640 Rodent Diet and water. The light cycle was 12 hours of dark followed by 12 hours 
of light, room temperature was 68 to 74°F and humidity was 55 to 60%.  All animal studies were 
approved by the University of Tennessee Institutional Animal Care and Use Committee. 
Animals were produced with brother by sister matings. Sires were removed from the 
breeder box when the dams were visibly pregnant. The day of birth was considered O days of 
age. Neonates were marked by toe-clipping during the first few days of life, and a single toe from 
each pup was saved to prepare DNA by the HotSHOT method (91 ). Briefly, toes were collected 
into 200 µI thermal cycler tubes .. Seventy-five microliters of 25 mM NaOH/ 0 .2  mM EDTA/ pH 12 
were added to the tubes. Samples were heated to 95 degrees C for 30 minutes, and then cooled 
to room temperature. Seventy-five microliters of 40 mM Tris HCI/ pH 5 were added to each tube 
to adjust the pH to 8, generating PCR quality DNA. 
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The fa mutation creates a restriction site for Msp I that can be used to detect fa genotype 
(92). However, Msp I occasionally fails to completely cut DNA, which can cause genotype 
misclassification. To overcome this problem, we engineered an alternative restriction site by a 
strategy that has been described previously (93). PCR primers were designed to amplify 101 
base pair (bp) of DNA flanking the fa mutation. The reverse primer, Rlepr, was selected to 
anneal adjacent to the site of the mutation , and a single base substitution (C-G) was made in 
the second base from the 3' end of the primer to create a Pvu II restriction site in the wildtype 
allele and no restriction site in the mutant allele. The primer sequences were flepr, 5'­
CGTATGGAAGTCACAGA-3', and Rlepr, 5'GAATTCTCTAAATATTTCAGC-3'; the base 
substitution in Rlepr is underlined. Primers were mixed at 500 nM each in 50mM KCI, 10mM 
Tris-HCI (pH 9 at 25°C), 0.1% Triton X-100, 1.5 mM MgCl2, 0.2 mM each dATP, dCTP, dGTP 
and dTTP, 0.25 units Taq DNA polymerase and 2 µI of HotSHOT DNA in a 22 µI volume. PCR 
amplification was carried out in a Robocycler thermal controller (Stratagene, La Jolla, CA) at 95°C 
for two min, followed by 40 cycles of 95°C for 30 sec, 45°C for 45 sec and 72°C for 30 sec. The 
PCR product was digested with 1 unit Pvu II (New England Biolabs, Beverly MA) in  a 30 µI 
volume for 1 h at 37°C. Thirty µI of Pvu II treated PCR product were loaded onto a 3% 3: 1 high­
resolution blend agarose (Amresco) gel and electrophoresed 30 minutes at 5 volts/cm. Gels 
were stained with ethidium bromide and exposed to UV l ight. The wildtype genotype produces an 
80 bp band, and the mutant genotype produces a 101 bp band; both bands are visible in 
heterozygotes. 
After genotyping, twelve l itters were reduced to 8 pups per litter (96 pups) by 
decapitating excess heterozygotes. Pups were weighed daiiy from 14 days of age; daily weighing 
acclimates the pups to handling and reduces stress when they are killed. Body weight was 
recorded to the nearest 0.01g in a file l inked to a Mettler PM2000 balance via Balancelink 
software (VWR Scientific, West Chester, PA). In this experiment, pups remained with their dam 
until they were killed. It should be noted that many investigators routinely separate the pups from 
the dam at 21 days of age. This practice interferes with growth and creates an investigator­
induced increase in the variation in data collected at this age. Sex-matched l ittermate wildtypes 
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and fatty rats were killed at 20 and 24 days of age for collection of tissue samples and 
heterozygotes were removed from the experiment. After removing heterozygotes, 45 subjects 
remained. The distribution of these subjects by age, genotype and sex is given in table 3. 
Stomachs, liver and inguinal adipose pads were dissected and weighed after the pups were 
decapitated. Stomach contents were then removed and empty stomachs were reweighed . The 
difference between full stomach weight and empty stomach weight was calculated to estimate the 
weight of the stomach contents. Inguinal adipose pads were frozen (in foil packets) in liquid 
nitrogen and stored at -80°C to be used for RNA extraction. 
RNA Extraction 
RNA was extracted from inguinal adipose tissue using modifications to the Totally RNA 
Total RNA Isolation kit (Ambion Inc., Austin, TX). Samples were homogenized in a guanidinium 
thiocyanate denaturation buffer, according to kit instructions. Then, in a departure from the kit 
instructions, the aqueous homogenate was extracted twice with 1 volume of chloroform to remove 
lipids. The remaining extraction and precipitation steps followed the kit instructions. After the 
RNA was precipitated with isopropanol, it was dissolved in DEPC water and precipitated with 
LiCI. One-half volume of 5 M LiCI was added to each sample. Samples were incubated 20 
minutes at -20° C and centrifuged at 10,000 x g for 15 minutes. The supernatant was discarded 
and the RNA pellet was washed with 300 �d 70% ethanol. The RNA was pelleted again and then 
dissolved in 300 µI of nuclease free water/ 0.1 mM EDT A Samples were stored at -80° C. 
Samples of purified RNA were diluted 1 00-fold in 1 mM Na2HPO4 buffer (pH 8.5) and UV 
absorbance was quantified spectrophotometrically at 260 and 280 nm (94). The ratio of 
absorbance at 260 nm to absorbance at 280 nm was calculated as an estimate of purity. The 
mean absorbance ratio was 1.99 ± 0.01 for these samples, which is close to the value of 2.00 
expected for pure RNA The concentration of nucleic acid was then calculated by the following 
formula: [RNA] µg/ml = Absorbance260 x 40.0 µg RNA per absorbance unit x 100 (dilution) .  The 
quality of the RNA was evaluated by agarose gel electrophoresis. RNA samples were prepared 
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Table 3. Distribution of subjects by age, genotype and sex. 
days of age genotype female male 
20 +/+ 5 5 
fa/fa 5 5 
24 +/+ 6 7 
fa/fa 6 6 
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and enough DEPC water to make a final volume of 20 �ti. The RNA was loaded on a 1 % agarose 
gel prepared with 0.2 M MOPS (pH 7.0), 50 mM sodium acetate, 10 mM EDTA, 0.22 M 
formaldehyde (added after the agarose is melted) and 0.5 µg/µI ethidium bromide. The same 
buffer was used as the electrophoresis buffer and the gel was electrophoresed at 75 volts for 3 
hours. Clear 28S and 18S ribosomal RNA bands indicated that the RNA was not degraded or 
contaminated with excess saits (figure 2). RNA was stored at -80°C for use later in microarray 
analysis and quantitative real-time RT-PCR. 
After isolation and assurance of intactness, four pools of RNA were prepared by mixing 5 
µg of RNA from 5 males in each genotype by age group: wildtypes at 20 days of age, fatty rats at 
20 days of age, wildtypes at 24 days of age and fatty rats at 24 days of age. RNA samples were 
shipped on dry ice to Genome Explorations (Memphis, TN) for Affymetrix GeneChip hybridization 
and quantification. U34A Rat Expression Arrays were used for hybridization. Because the 
expression data was based on pooled RNA samples with no replication, no statistical analysis of 
the data is possible. However, the magnitude of the gene expression changes are large enough 
that 2-fold changes in gene expression are likely to represent real changes. Thus, transcripts that 
were differentially expressed a minimum of 2-fold by genotype within age or 2-fold by age within 
genotype were identified for further investigation. Of the transcripts identified , specific transcripts 
of interest were selected for their involvement as key regulatory steps in pathways of lipogenesis 
and cholesterol synthesis. Primers and probe sets were ordered for selected transcripts through 
Applied Biosystems Assays by Demand. 
Real Time Quantitative RT-PCR 
The results of the GeneChip analysis were validated by real time RT-PCR of a selection 
of transcripts including: farnesyl diphosphate synthase, stearoyl CoA desaturase 1, malic 
enzyme, transketolase, lipoprotein lipase, leptin, insulin induced gene 1, glycerol 3-phosphate 
acyltransferase and fatty acid synthase. Peroxisome proliferator activated-receptor y was not 
present on the Genechip, but was chosen for RT-PCR because it is an important transcription 
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Figure 2. Example of 28S and 18S ribosomal RNA. RNA was run on 1 % denaturing agarose 
gel. The clear bands demonstrate that RNA is not degraded or contaminated with excess salts. 
All RNA samples were evaluated by this method to ensure quality. 
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factor in lipogenesis. Reverse transcription polymerase chain reaction allows RNA to be 
converted into DNA and to be amplified by PCR. This is a sensitive method for detection of 
specific transcripts, particularly of RNA in low abundance or in small sample amount. The first 
stage of reverse transcription PCR is mediated by a reverse transcriptase that converts RNA into 
its complementary single-stranded DNA, called first strand synthesis. Using the first strand as a 
template, the first strand of DNA is converted into a double strand by synthesis of the second 
strand. 
In the final stage, cDNA undergoes exponential amplification in . the PCR reaction. 
Protocols and instruments to monitor the accumulation of PCR product continuously (real time 
RT-PCR) have made the techniques highly quantitative. A dual-labeled fluorescent probe, in this 
case a Taqman probe, forms the basis of the detection system (figure 3). At the 5' end of the 
Taqman probe is the reporter dye and at the 3' end is the quencher dye. The intact probe 
hybridizes to the target amplicon downstream from the primer. At this point the reporter and 
quencher dyes are in close enough proximity that the reporter emission is quenched. However, 
during the extension phase of the PCR cycle, the DNA polymerase with 5 ' to 3 '  nuclease activity 
degrades the probe, releasing the reporter dye and the quencher from the DNA strand. Because 
they are no longer close enough for the reporter to be quenched, the amount of fluorescence in 
solution increases as the PCR product accumulates. It is the fluorescence emission of the 
reporter that is monitored continuously during RT-PCR amplification. The first cycle in which a 
significant increase in fluorescence above the background, or fluorescent signal derived from 
unbound or non-specific cleavage of probe, occurs is termed the cycle threshold (figure 4). CT is 
proportional to the log of the concentration of the RNA, so simple linear regression between CT 
and the log of a series of dilutions of an RNA pool generate a straight line that can be used to 
estimate the relative concentration of RNA in unknown samples (figure 5). 
Core reagents for RT-PCR, including 25 mM MgCl2, 10 mM dATP, 10 mM dCTP, 10 mM 
dGTP, 1 0  mM dTTP, MuLV-RT and Rnase inhibitor were obtained from GeneAmp RNA PCR kits 
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Polymerization 
forward primer TaqMan probe 
�3' 
3' ---------------------- 5' 
PCR primer 1 
PCR primer 2 
5' ---------------------- 3' 
reverse primer 
Strand displacement and cleavage 
forward primer TaqMan probe 
3' ---------------------- 5' 
PCR primer 1 
PCR primer 2 
5' ---------------------- 3' 
reverse primer 
Figure 3. Depiction of reverse transcription PCR. PCR primers and a Taqman probe, containing 
a reporter dye (R) at the 5' end and a quencher dye (Q) at the 3' end, bind to the DNA template. 
The Taq DNA polymerase allows the primer to extend eventually cleaving the Taqman probe. In 
cleaving the probe, the reporter dye is cleaved from the quencher dye by the DNA polymerase 
resulting in the emission of fluorescence by the reporter. The accumulation of PCR products is 
monitored by the increasing fluorescence of the reporter dye. 
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Figure 4. Threshold cycles for standard curve of farnesyl diphosphate synthase. A serial dilution 
was performed generating 6 RNA concentrations from which the dilution curve was developed. 
The concentrations of each of the six points of the standard curve were: 250, 62.5, 15.625, 
3.906, 0.976, 0.244 ng/µI. 
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Figure 5. Standard curve for farnesyl diphosphate synthase. A serial dilution was performed 
generating 6 RNA concentrations from which the dilution curve was developed. The 
concentrations of each of the six points of the standard curve were: 250, 62.5, 1 5.625, 3.906, 
0.976, 0.244 ng/µI. 
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(Applied Biosystems, Foster City, CA). AmpliTaq Gold and 10X Taqman buffer A were obtained 
from a Taqman 1000 reaction Gold/ Buffer A Pack purchased from Applied Biosystems. Assays 
on Demand primers and probes for most assays were obtained from Applied Biosystems (table 
4). Primers and probes for PPARy, FAS and 18S RNA were synthesized commercially (table 5). 
For each set of RT-PCR reactions, a master mix was prepared by mixing 7.35 µL DEPC 
water, 2.5 µL 10X Taqman buffer A, 5.5 µL of 25 mM MgCl2, 0.75 �LL of each 10 mM dNTP, 0.125 
µL of 50U/µL Mul VRT, 0. i 25 µL of 20U/µL RNase inhibitor, 0.1 5  µL of 50U/µL AmpliTaq Gold 
and 1.25 µL of primer and probes mix to make a 20 µL volume. A standard dilution cur
v
e was 
established by performing a serial dilution of pooled RNA resulting in 6 concentrations of RNA at 
50, 12.5, 3.125, 0.781, 0.195 and 0.049 ng/µL Five µL of standard and unknown RNAs diluted to 
2.5 ng/µL were added to separate tubes for a final volume of 25 µL. Samples were centrifuged 
and loaded into a Smart Cycler Real Time PCR System (Cepheid, Sunnyvale, CA). Amplification 
was performed in a Smart Cycler Real Time PCR System (Cepheid , Sunnyvale, CA). The 
reactions was performed using a 3-stage cycling protocol: stage 1 at 48.0° C for 30 minutes, 
stage 2 at 95.0°C for 10 minutes, and stage 3 which consisted of 50 two-temperature cycles, 
95°C for 15 seconds followed by 60°C for 60 seconds. Reverse transcription occurs in stage 1, 
inactivation of rev&rse transcriptase and denaturation occurs in stage 2 and denaturation , 
annealing and extension occurs during stage 3. 
After completion of the RT-PCR reaction, linear regression was performed with CT values 
for the standards and the log of the RNA amount in the given tube was determined. This 
regression line was then used to estimate the relative expression of the unknowns based on their 
CT values. The units are arbitrary. To adjust for variation in starting RNA amount, the estimates 
were divided by 18S RNA expression levels for the same sample. 
Data Analysis 
A control group pre-test/post-test design was used to examine the research questions. 
Twenty- two wildtype rats served as the control group and the test group was comprised of 23 
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Table 4. Applied Biosystems Assays by Demand primers and probes. 
transcript name and symbol 
malic enzyme (Me1) 
transketolase (Tkt) 
glycerol 3-phosphate acyltransferase, mitochondrial (Gpam) 
farnesyl diphosphate synthase (Fdps) 
insulin induced gene 1 (lnsig 1) 
leptin (Lep) 
lipoprotein lipase (Lpl) 
stearoyl CoA desaturase 1 (Scd 1) 
Table 5. RT-PCR primer and probe concentrations and compositions. 
oligo concentration sequence 
FAS for 200 nM CCCAGAGGCTTGTGCTGACT 
FAS rev 400 nM CGAATGTGCTTGGCTTGGT 
affymetrix assay ID 
Rn00561502_m1 
Rn00574981_m1 
Rn00568620_m1 
· Rn00821389 _g1 
Rn00574380_m1 
Rn00565158_m1 
Rn00561482_m1 
Rn00594894_g1 
FAS probe 100 nM TET d (CCGATCTGGAATCCGCACCGG) TAMRA 
PPAR for 200 nM TGCGAGTGGTCTTCCATCAC 
PPAR rev 400 nM GCCTTGAGCACTTCACAAGAAATT 
PPAR probe 100 nM CAL RED d (TTTGCCAAGCTGCTCCAGAAAA TGA) BHQ-2 
18S for 200 nM AGTCCCTGCCCTTTGTACACA 
18S rev 400 nM GATCCGAGGGCCTCACTAAAC 
18S probe 100 nM 6-FAM d (CGCCCGTCGCTACTACCGATTGG) BHQ-1 
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fatty rats. The find ings are based on data derived from both groups at 20 and 24 days of age. If  
hyperphagia is developmentally related , d ifferences between the two genotypes should be 
exhibited within the four-day period. Independent-samples t-tests were employed to analyze the 
d ifference of means between the two genotypes on inguinal fat pad mass, body weight, stomach 
mass, and stomach content and 20 and 24 days of age. 
Additionally, SAS's "proc mixed" routine was used to control for the effects of litter and to 
determine the presence of interactive effects. "Proc mixed" was designed to model both random 
and mixed effect data. The procedure is built on the analysis of variance (ANOVA) statistical 
routine, and returns F values and probability values for each model. It also provides means and 
standard errors for each fixed effect factor. For the models d iscussed below, transcript 
expression level, inguinal fat pad mass, body weight, stomach mass, and stomach content served 
as the dependent variables of interest. Genotype, age and sex were treated as fixed effects 
factors and litter was defined as a random effects factor (figure 6) .  
RESULTS 
Development of Hyperphagia 
I t  has previously been demonstrated that the fatty rat grows at the same rate as their 
littermates for the first 22 days of age, and then begins to g row at a higher rate because of the 
sudden onset of hyperphagia (74). This pattern was repeated in this experimental population. 
Body weights were affected by genotype, age, genotype by age interaction and by sex (table 6A). 
The effect of sex is quantitative and not qualitative, the pattern of change is similar in males and 
females. Because we are not particularly interested in the sex effects unless they are 
qualitatively d ifferent between the sexes, the graphs present the sex-averaged means for 
wildtypes at 20 and 24 days of age and fatty rats at 20 and 24 days of age (figure 7). 
The body weights of wi ldtypes and fatty rats were similar at 20 days of age, but by 24 
days of age fatty rats were heavier than wildtypes (figure 7) .  Daily gain was affected by age and 
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options linesize = 72; options pagesize = 20000; 
options nodate; options nonumber; run; 
data one; 
infile ' i :/Mary/switchdata.txt' FIRSTOBS=2; 
input id lit age geno sex $ body gain liver ing stom MT contents r1 8s fas pparg Scd1 
Me1 Lep Gpam Tkt Fdps lnsig1 Lpl; 
run; 
%macro mixed (yvar); 
proc mixed; 
class id lit geno age sex; 
model &yvar=genolage!sex; 
random lit; 
lsmeans geno*age /slice=age slice=geno; 
run; 
%mend mixed; 
%mixed (body);¾mixed (gain);¾mixed (liver);%mixed (ing);¾mixed (stom) ;  
%mixed (MT); %mixed (contents); %mixed (r1 8s); 
%mixed (fas) ;¾mixed (pparg);¾mixed (Scd1 ) ;%mixed (Me1 ); %mixed (Lep); 
%mixed (Gpam); %mixed (Tkt); %mixed (Fdps); %mixed ( lnsig1 ) ;  %mixed (Lpl); 
Figure 6. SAS code used for statistical analysis of all data. 
Table 6A. Type 3 tests of fixed effects for body weight. 
effect num DF den DF F Value Pr > F 
geno 1 27 7.41 0.01 1 2  
age 1 27 99.79 <.0001 
geno*age 1 27 1 4 .06 0.0009 
sex 1 27 1 1 .94 0.001 8  
geno*sex 1 27 0.1 7 0.681 8 
age*sex 1 27 0.1 5  0.7026 
geno*age*sex 1 27 0.91 0.3489 
50 
60 
50 
"' 40 E -
- 30 -:c 
Cl 
-� 20 -
1 0  
0 
body weight 
+/+ (a/fa 
20 
age, days 
p<O .oo..-o_._...., 
+/+ fa/fa 
24 
� 2 . 5  
c 2 
"iii 
Cl 
.2:- 1 . 5-
0.5  
0 
daily gain 
p= 0.01 3 
+f+- fa/fa 
20 
age, days 
+/+ fa/fa 
24 
Figure 7. Body weights and daily gain of wildtype and fatty rats at 20 and 24 days of age. Body 
weights of fatty rats and wildtypes were similar at 20 days of age. By 24 days, fatty rats were 
significantly heavier than wildtypes (p<0.0001). Daily gain of wildtypes at 20 days of age was 
significantly higher than fatty rats (p=0.013), but fatty rats gained significantly more than wildtypes 
at 24 days of age (p=0.0010). 
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genotype by age interaction (table 68). The interaction between age and genotype is such that 
daily gain is lower in fatty rats compared to wildtypes at 20 days of age, but daily gain is greater in 
fatty rats than wildtypes by 24 days of age (figure 7). 
Daily gain of the fatty rat more than doubles between 20 and 24 days of age suggesting 
that an increase in food intake could be occurring in this interval. Because food intake is not 
measurable in litters of pups that are suckling and consuming solid food, without separating the 
pups from the dam and altering the experimental conditions, we use the weight of the stomach 
contents as a proxy estimator of food intake at these ages. The genotype by age effect is the 
major influence on stomach weight (table 7 A) and weight of the stomach contents (table 78). In 
contrast, the weight of the stomach itself is affected only by age (table 7C). These differences 
reflect the fact that full stomach weight and stomach contents are similar between wildtypes and 
fatty rats at 20 days of age, but are increased in fatty rats compared to wildtypes at 24 days of 
age. Furthermore, the weight of the empty stomach is similar between wildtypes and fatty rats at 
both 20 and 24 days of age. Thus, the increase in stomach weight is accounted for by an 
increase in stomach contents and not by an increase in the stomach tissue proper (figure 8). 
These data suggest that fatty rats are not hyperphagic at 20 days of age, but are hyperphagia by 
24 days of age. 
The genotype by age effect is also the major influence on liver weight (table 8A) because 
the liver weights are similar between wildtypes and fatty rats at 20 days of age but greater in fatty 
rats at 24 days of age (figure 9). The increase in liver weight is another indicator that fatty rats 
are hyperphagic at this age. Finally, genotype is the major influence on inguinal adipose pads 
weight (table 88). This is consistent with the observation that fatty rats accumulate excess fat 
mass before the emergence of hyperphagia through reduced energy expenditure. Age is also an 
important influence on inguinal adipose mass and the genotype by age effect is relatively small 
(table 88). These effects indicate that the fatty rat has much greater fat mass even before the 
onset of hyperphagia, fat mass continues to expand in both genotypes at this age, and there is an 
increase in the rate of gain of adipose mass in fatty rats compared to wildtypes in this interval 
(figure 9). 
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Table 6B. Type 3 tests of fixed effects for daily gain. 
effect num DF den DF F Value Pr > F 
gene 1 27 0.23 0.6345 
age 1 27 68.31 < .0001 
geno*age 1 27 19.78 0.0001 
sex 1 27 2.26 0.1441 
gene*sex 1 27 0.05 0.8201 
age*sex 1 27 0.02 0.8924 
geno*age*sex 1 27 0.05 0.81 96 
Table 7 A. Type 3 tests of fixed effects for stomach weight. 
effect num DF den DF F Value Pr > F 
gene 1 27 1 0 .77 0.0029 
age 1 27 1 1 .06 0. 0026 
geno*age 1 27 29.53 < .0001 
sex 1 27 0.68 0.4173 
geno*sex 1 27 0.25 0.6224 
age*sex 1 27 0.01 0.9241 I 
geno*age*sex 1 27 0.01 0.9409 
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Table 78. Type 3 tests of fixed effects for stomach contents. 
effect num DF den DF F Value Pr > F 
geno 1 27 9 .29 0 .0051 
age 1 27 7.22 0.0122 
geno*age 1 27 24.77 <.0001 
sex 1 27 0.74 0.3986 
geno*sex 1 27 0.05 0.8255 
age*sex 1 27 0.01 0.9116 
geno*age*sex 1 27 9.29 0.0051 
Table 7C. Type 3 tests of fixed effects for empty stomach. 
effect num OF den DF F Value Pr > F 
geno 1 27 0.05 0 .8220 
age 1 27 27.66 <.0001 
geno*age 1 27 0.71 0.4057 
sex 1 27 0 0. 9561 
geno*sex 1 27 1.73 0 .1993 
age*sex 1 27 0 0.9854 
geno*age*sex 1 27 1.2 0.2824 
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Figure 8. Stomach, stomach contents and empty stomach weights of wildtype and fatty rats. 
Stomach, stomach contents and empty stomach weights are similar between wildtypes and fatty 
rats at 2 0  days of age. By 24 days, fatty rats stomach contents were significantly heavier than 
wildtypes (p<0.0001 )  while empty stomach weights are the same. The increased stomach 
weight fatty rats experience at 24 days of age is a result of increased stomach contents 
compared to wildtypes (p<0.0001 ). These data suggest that the onset of hyperphagia occurs in 
the fatty rat after 20 days of age but before 24 days of age. 
Table BA. Type 3 tests of fixed effects for liver weight. 
effect num OF den OF F Value Pr > F 
geno 1 27 1 7.37 0.0003 
age 1 27 76.98 <.0001 
geno*age 1 27 1 5.51 0.0005 
sex 1 27 1 3.93 0.0009 
geno*sex 1 27 2.03 0.1 653 
age*sex 1 27 0 0.9746 
geno"'age*sex 1 27 0.24 0.6259 
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Figure 9. Liver and inguinal adipose pads weight of wildtype and fatty rats at 20 and 24 days of 
age. Liver weight are similar in rats at 20 days of age, however by 24 days of age fatty rats livers 
weight significantly more than wildtypes (p<0.0001). Fatty inguinal adipose pads weighed 
significantly more at both 20 days of age and 24 days of age (p<0.0001 ) .  
Table 8B. Type 3 tests of fixed effects for inguinal adipose pads 
weight. 
effect num DF Den OF F Value Pr > F 
geno 1 27 283.53 <.0001 
age 1 27 34.19 <.0001 
geno*age 1 27 12.6 0.0014  
sex 1 27 0.53 0.4725 
geno*sex 1 27 0.58 0.4530 
age*sex 1 27 0.08 0.7740 
geno*age*sex 1 27 0 0.9830 
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Transcriptional Profiling 
The onset of hyperphagia might be expected to be associated with changes in pathways 
in adipose tissue of fatty rats. Pathways that are differentially expressed in fatty rats before the 
onset of hyperphagia are likely to be more closely related to leptin signaling than those that are 
differentially expressed after the emergence of hyperphagia and hyperinsulinemia. To identify 
which pathways are differential ly expressed prior to the onset of hyperphagia and after the onset 
of hyperphagia, transcriptional profiling was performed using Affymetrix Genechips on inguinal 
adipose tissue in male wildtype and fatty rats at 20 and 24 days of age. 
At 20 days of age, before the onset of hyperphagia, 52 transcripts were downregulated 
by -2-fold or more in fatty rats and 25 transcripts were upregulated by 2-fold or more in fatty rats 
(table 9) .  Fifteen transcripts that were differentially expressed were involved in the immune 
system or inflammation, consistent with the known role of leptin signaling in regulation of the 
immune system. Eleven of these were downregulated in fatty rats and 4 were upregulated. 
Another 1 3  transcripts related with the cytoskeleton were all downregulated in fatty rats. These 
and many other downregulated transcripts W-enolase 3, calcium ATPase, creatine kinase, etc.) 
are likely to be involved with muscle cell phenotype during differentiation. Leptin, as expected , 
was upregulated 2.8 fold in fatty rats already at 20 days of age. The transcripts that had the 
greatest levels of upregulation were stearoyl CoA desaturase 1 (6.5-fold ) ,  stearoyl CoA 
desaturase 2 (6. 5-fold) and natriuretic factor receptor C (9.2-fold). Natriuretic factor receptor 3 is 
involved in the regulation of blood pressure, and might be directly regulated by leptin signaling. 
Stearoyl CoA desaturases are principally considered to be responsible for the conversion of 
saturated fatty acids to monounsaturated fatty acids, and can be considered to be components of 
lipogenic pathways. However, no other lipogenic enzymes are upregulated at 20 days of age in 
fatty rats, suggesting alternative roles for Scd1 at this age. By 24 days of age, 27 transcripts are 
downregulated in fatty rats and 49 transcripts are upregulated (table 1 0) .  Prominent among the 
upregulated transcripts are enzymes involved in growth, glucose metabolism, lipogenesis, fatty 
acid oxidation and insulin signaling. When the lists of differential ly expressed transcripts at 20 
and 24 days of age are compared, 1 0  transcripts are differentially expressed at both ages. These 
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ffects on inguinal adipose tissue transcripts at 20 days of age. 
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Pro
beset 
* 
T
ranscript 
D
 
Pathw
ay 
S
69160_s_at 
thyrotropin releasing horm
one receptor 
2.6 
TR
H
 receptor 
S79624_at 
5 
natriuretic peptide receptor subl 
* 
9.2 
natriuretic receptor 
rc_A
I012275_at 
developm
entally regulated prote::11, , fJU 1 
-3.0 
polyam
ine transporter 
D
84418_s_at 
chrom
osom
al protein H
M
G
2 
-2.1
 
transcription 
A
F055286 _g_at 
organic cation transporter 3; O
ct3 
-5.3 
transcription 
X
60769m
R
N
A
_
at 
sfb m
R
N
A
 for silencer factor B 
-2.0 
transcription; inhibits G
S
T expression 
M
83679_at 
R
A
B15, m
em
ber R
A
S onocogene fam
ily 
2.8 
transcription; protein transport 
J03190 _g_ at 
5-am
inolevulinate synthase 
-3.2 
hem
e synthesis 
L32601_s_at 
20 a-hydroxysteroid dehydrogenase 
2.8 
progesterone m
etabolism
 
D
28560_g_at 
phosphodiesterase I 
2.8 
phosphodiesterase; adenosine synthesis 
D
14015_g_at 
cyclin E 
2.3 
kinase, cell cycle 
X
95986m
R
N
A
#
1 _f_at 
carbonyl reductase 1 
-2.8 
N
A
D
P
H
-dependent oxidoreductases 
D
14046_at 
D
N
A
 topoisom
erase 118
 
2.1 
D
N
A
 topological change 
X
04139_s_at 
protein kinase C
 
-5.7
 
cell signaling; grow
th 
rc_A
A
800315_at 
sim
ilar to PxF protein (LO
C
289233) 
-3.7 
peroxisom
e biogenesis 
J05592_g_at 
protein phosphatase inhibitor-1 protein 
-2.0 
cell signaling; glycogen m
etabolism
 
S
63521_i_at 
6 
glucose-regulated protein G
R
P
7
8 
-7.0 
protein trafficking; regulated by glucose 
X
13411cds_s_at 
elk protein 
3.0 
tyrosine kinase; insulin signaling 
M
64301_at 
m
itogen activated protein kinase 6 (M
A
PK
6) 
-2.3 
cell signaling; cell cycle 
M
81183Exon_UT
R_g_at 
7
 
insulin-like grow
th factor 
I 
-2.5 
grow
th regulation 
D
45862_g_at 
8 
leptin 
2.8 
lipid m
etabolism
; im
m
une system
 
rc_A
l17
5764_s_at 
9 
stearoyl-C
o A
 desaturase 1 
6.5 
lipogenesis; fatty acid desaturation 
A
F0367
61 g
 at 
10 
stearol'.'.1-C
oA
 desaturase 2 
6.5 
liQogenesis; fatty
 acid desaturation 
N
um
ber affected 
52 
25 
* T
ranscripts that are differentially expressed by genotype at 20 and 24 days of age are m
arked w
ith these num
bers in the tw
o tables. 
D
, fold decrease in fatty rats com
pared to w
ildtypes. 
I, fold increase in fatty rats com
pared to w
ildtypes. 
T
able 10. G
enotype effects on inguinal adipose tissue transcripts at 24 days of age. 
P
robeset 
* 
Transcriet 
D
 
P
athw
ay:
 
X
07189cds_at 
lg 1:: chain constant region 
-3.2 
im
m
une system
 
U
39609_s_
at 
1 
im
m
unoglobufin K light chain variable 
-3.0 
im
m
une system
 
M
18528cds_f_at 
2 
lg germ
line K-chain C
-region gene 
-2.6 
im
m
une system
 
X
07551cds_s_at 
B-alpha gene for class II antigen 
-2.1 
im
m
une system
 
S
79711_g_at 
3 
C
D
3 y-chain 
-2.1
 
im
m
une system
 
X
14319cds_g_at 
4 
T-cell receptor p chain 
-2.1 
im
m
une system
 
U
75411cds_g_at 
anti-idiotype im
m
unoglobulin M
 light chain 
-2.0 
im
m
une system
 
U
86379_at 
anaphylatoxin C
3a receptor 
4.0 
im
m
une system
 
rc_A
l171243_at 
sim
ilar to replication protein A
3 
-2.3 
D
N
A
 replication 
U75689_s_at 
D
N
ase y 
-7.0 
apoptosis 
S
61865_s_at 
syndecan 
-2.0 
cell adhesion; apoptosis 
rc_A
I011706_at 
sim
ilar to splicing factor S
R
P20 
-2.1
 
m
R
N
A
 synthesis 
Y
17295cds_s_at 
peroxiredoxin 6 
2.0 
antioxidant 
M
84719_at 
flavin-containing m
onooxygenase 1 
-2.1
 
xenobiotic m
etabolism
 
.....
 
S
72505_f_at 
glutathione S
-transferase Y
c1 subunit 
2.1 
xenobiotic m
etabolism
 
(0
 
U
36895_at 
vom
eronasal receptor 3 
4.9 
vom
eronasal receptor 
A
F034899_i_at 
olfactory receptor gene O
lr1699 
4.0 
olfactory
 receptor 
S
79624_
at 
5 
natriuretic peptide receptor subtype C
 * 
2.8 
natriuretic receptor 
rc_A
I072634_
at 
keratin com
plex 1, acidic, gene 18 
-2.5 
cytoskeleton 
re _AA
892248 _g_ at 
ES
T
196051 
-2.5 
cytoskeleton 
rc_A
A
893032_at 
sim
ilarity to �-galactosidase (lactase) 
2.0 
lactase 
J00711_at 
�-casein 
2.1 
calcium
 binding 
rc_A
I010725_g_at 
calnexin 
-2.3 
calcium
 binding, protein trafficking 
S
63521�
i_at 
6 
glucose-regulated protein G
R
P
78 
-2.0 
calcium
 binding, protein trafficking 
A
J001044cds_at 
EG
P
-314 protein hom
ologue 
-2.1 
calcium
 signal transducer 
L 13445 at 
sial}'.'.ltransferase g
ene fam
il}'.'. related m
R
N
A
 
2.0 
g
l}'.'.COS}'.'.lation Of e
roteins 
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P
ro
beset 
* 
T
ranscrie
t 
D
 
P
athw
ar
 
U
507
17
 _s_at 
synaptic density protein P
S
D
-93 
4.3 
com
ponent of synapses 
U
0797
1_at 
L-arginine-glycine am
idinotransferase 
3.2 
A
T
P
 buffer; creatine synthesis 
M
59460m
R
N
A
#2_
at 
liver glycogen phosphorylase 
2.0 
glycogen m
etabolism
 
S
56464m
R
N
A
_
g_
at 
hexokinase 11 
2.1 
glycolysis 
rc_A
A
924326_s_at 
aldolase
A 
2.3 
glycolysis and gluconeogenesis 
O
00092_s_
at 
pyruvate dehydrogenase 
2.3 
glycolysis and gluconeogenesis 
U
32314_at 
pyruvate carboxylase 
2.0 
glycolysis and gluconeogenesis 
L22294_at 
pyruvate dehydrogenase kinase 
2
.1 
glycolysis and gluconeogenesis 
M
81183Exon_
U
T
R
_
g_
at 
7 
insulin-like grow
th factor I 
-2.3 
grow
th regulation 
J04486_at 
insulin grow
th factor-binding protein 
-4.3 
grow
th regulation 
A
09811cds_s_at 
IG
F binding protein 2 
-5.7
 
grow
th regulation 
S
49003_s_at 
short isoform
 grow
th horm
one receptor 
2.0 
grow
th regulation 
Z
83757m
R
N
A
_
at 
grow
th horm
one receptor 
2.0 
grow
th regulation 
S
56481_s_at 
[3
3 adrenergic receptor 
-2.0 
lipolytic regulator 
N
 
rc_A
l639525_at 
adiponutrin 
4
.6
 
adipocyte specific lipase 
tO
 
rc_M
893242_g_at 
fatty acid C
oA ligase, long chain 2 
2.3 
fatty acid oxidation 
0
43623 _g_ at 
carnitine palm
itoyltransferase I like protein 
2.0 
fatty acid oxidation 
D
45862_g_at 
8 
leptin 
2.5 
lipid m
etabolism
; im
m
une system
 
L27075_g_at 
citrate lyase 
3.0 
lipogenesis 
J03808_at 
acetyl C
oA
 carboxylase 
4
.6
 
lipogenesis, 
X
13527cds_s_at 
acyl carrier protein dom
ain of fatty acid synthase 
3.2 
lipogenesis; 
M
767
67 _s_at 
fatty acid synthase 
2.5 
lipogenesis; fatty acid synthesis 
M
26594_at 
m
alic enzym
e 
8.6 
lipogenesis; N
A
D
P
H
 production 
rc_A
I 175764_s_at 
9 
stearoyl-C
o A desaturase 1 
3.2 
lipogenesis; fatty acid desaturation 
A
F0367
61_g_at 
10
 
stearoyl-C
oA desaturase 2 
4
.0 
lipogenesis; fatty acid desaturation 
A
B002558_at 
glycerol 3-phosphate dehydrogenase 
2.1 
lipogenesis; glycerol 3-phosphate synthesis 
U36773 g
 at 
911cerol-3-e
hose
hate ac:lltransferase 
2.6 
lieogenesis; trigl1ceride s:tnthesis 
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P
robeset 
.. 
T
ranscriet 
D
 
P
athw
ai 
rc_A
l180442_at 
farnesyl diphosphate synthase 
2.3 
lipogenesis; cholesterol synthesis 
rc_A
I236145_at 
hydroxysteroid dehydrogenase 17
 beta, type 7 
5.3 
lipogenesis; cholesterol synthesis 
rc_A
I059508_s_at 
transketolase 
2.6 
pentose phosphate pathw
ay 
rc_A
A
875025_at 
cellular retinoic acid binding protein I 
-3.2 
retinol binding; adipocyte differentiation 
K
03045cds _r _ at 
retinol-binding protein gene 
2.6 
retinol binding; adipocyte differentiation 
A
J223355_at 
m
itochondrial dicarboxylate carrier 
2.0 
adipocyte developm
ent 
K
01934m
R
N
A#2_at 
hepatic product spot 14
 
2.0 
transcription of lipogenic genes 
L 13619_g_at 
insulin-induced grow
th-response, insig-1 
2.1 
transcription of lipogenic genes 
U
09540_at 
cytochrom
e P
450 
-2.5 
m
ixed function m
onooxygenase 
X
99477cds_at 
phosphotriesterase-related protein 7 
3.7 
hydrolysis of phosphotriesters 
D
84667 _g_at 
phosphatidylinositol 4-kinase 
-7.0 
Pl 4,5-bisphosphate synthesis 
U
02553cds_s_at 
dual specificity phosphatase 1 
2.1 
insulin signaling; P
l signaling 
X
94185cds_s_at 
dual specificity phosphatase 6 
-2.3 
cell signaling; differentiation 
X
16476cds_at 
drk1 gene m
R
N
A
 for potassium
 channel protein 
4.0 
insulin regulated potassium
 channel 
J00801_at 
w
hey acidic protein 
3.7 
protease inhibitor 
rc_A
l639241_at 
sim
ilar to ubiquitin carboxyl-term
inal hydrolase 12
 
2.5 
protein turnover 
rc_A
l102868_g_at 
phosphoserine am
inotransferase 1 
2.1 
serine synthesis 
S
59
158_at 
glutam
ate transporter 
-2.0 
glutam
ate transport 
A
F 104399 _g_ at 
m
elanocyte-specific gene 1 protein 
-2.0 
transcription 
A
F036335 _g_at 
NonO
/p54nrb hom
olog 
-2.8 
transcription 
rc_A
A
892863_at 
sim
ilar to m
itochondrial carrier hom
olog 2 
2.3 
unknow
n 
rc_A
I639074_at 
R
at m
ixed-tissue library cD
N
A
 clone rx01925 
24.3 
unknow
n 
re A
l639
112
 at 
R
at m
ixed-tissue libral}'.
 cD
N
A
 clone rx04824 
7. 5 
unknow
n 
N
um
ber affected 
27 
4
9 
* Transcripts that are differentially expressed by genotype at 20 and 24 days of age are m
arked w
ith these num
bers in the tw
o tables. 
D
, fold decrease in fatty rats com
pared to w
ildtypes. 
I, fold increase in fatty rats co
m
pared to w
ildtypes. 
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include four transcripts with immune system functions: immunoglobulin K light chain variable 
region, immunoglobulin  K-chain constant region, CD3 y-chain, and T-cell receptor �-chain, all 
downregulated at both ages. Natriuretic peptide receptor type C is upregulated 9 .8 fold in fatty 
rats at 20 days of age and 2.8 fold at 24 days of age. Glucose regulated protein 78, an 
endoplasmic reticulum protein that is normally upregulated in cells under starvation, is 
downregulated -7-fold at 20 days of age and -2-fold at 24 days of age. Insulin-like growth factor I , 
a growth factor involved in adipocyte development, is downregulated -2.5-fold at 20 days of age 
and -2.3-fold at 24 days of age. Leptin is upregulated at both ages, as expected. Stearoyl CoA 
desaturase 1 and stearoyl CoA desaturase 2 are upregulated 6.5-fold at 20 days of age, and 3.2-
fold and 4.0-fold, respectively, at 24 days of age. 
Validation of differential expression results 
Real-time RT-PCR was performed to confirm the results of the microarray analysis. 
Lipogenic enzymes fatty acid synthase, malic enzyme, transketolase, glycerol 3-phosphate 
acyltransferase and farnesyl diphosphate synthase were first tested. Afterwards, transcriptional 
regulators peroxisome proliferator activated-receptor y and insulin induced gene 1 were 
confirmed with RT-PCR. Lastly, transcripts differentially expressed at both 20 days of age and 24 
days of age, including stearoyl CoA desaturase 1, leptin and lipoprotein lipase were selected and 
the microarray results were confirmed. 
18S ribosomal RNA is involved in protein synthesis and accounts for a large proportion 
of the RNA in any total RNA sample. 18S RNA was measured in all samples to serve as a 
control. To confirm that 18S RNA was not affected by any variables under investigation, we 
analyzed the effect of age, genotype and sex on 18S RNA expression (table 11 ). None of these 
variables ortheir interactions had any significant effect on 18S RNA expression, verifying that it is 
an appropriate control. The remaining transcripts were all expressed as ratios relative to 18S 
expression to improve the power of the statistical analysis by adjusting for amount of RNA in each 
sample. 
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Table 1 1 . Type 3 tests of fixed effects for 1 8S RNA. 
effect num DF den DF F Value Pr > F 
geno 1 27 0.02 0.8969 
age 1 27 0.9 0.3508 
geno*age 1 27 1 . 1 9  0.2840 
sex 1 27 0.47 0.4969 
geno*sex 1 27 0.02 0.8847 
age*sex 1 27 0.09 0. 761 8 
geno*age*sex 1 27 0.22 0.6462 
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Fatty acid synthase (FAS) is a transcript that represents the regulation of synthesis of 
saturated fatty acids (47). FAS expression was effected by genotype, age, sex and all 
interactions (table 12A). FAS expression was low in wildtypes and fatty rats at 20 days of age, 
and there were no differences between the genotypes at this age (figure 10). By 24 days of age, 
FAS expression was 13.5-fold greater in fatty rats than in wildtypes (figure 10). In comparison, 
the arrays detected a 2.5-fold difference in expression at 24 days of age, suggesting that the 
arrays underestimate expression of this transcript (table 10). 
Farnesyl diphosphate synthase (Fdps) is an enzyme required in the synthesis of 
cholesterol and its derivatives (57). Fdps was affected by genotype, age and all genotype 
interactions (table 12B). Fdps expression was similar at 20 days of age in wildtypes and fatty rats 
(figure 10). At 24 days of age, fatty rat expression was upregulated 2 .2-fold (figure 10). 
Additionally, the array results estimated a 2.3-fold increase in fatty rats, compared to wildtypes at 
24 days of age (table 10). 
Malic enzyme (Me1) catalyzes the reversible oxidative decarboxylation of malate forming 
pyruvate and NADPH, which provides reducing equivalents for lipogenesis (50). Malic enzyme 
expression was affected by genotype, age and all genotype interactions (table 13A). Me1 
expression at 20 days of age illustrated no statistical difference between wildtype and fatty rats 
(figure 11 ). However, by 24 days of age, fatty rats experienced a nearly 7.5-fold increase in  
expression compared to wildtypes (figure 11 ) .  The array results detected a 8.6-fold increase at 
24 days of age (table 10). 
Transketolase (Tkt) is a transcript linking glycolysis with the pentose phosphate pathway, 
which also produces NADPH to serve as reducing equivalents for fatty acid synthesis (49). Tkt 
was expressed at similar levels in wildtype and fatty rats at 20 days of age (figure 11 ). While the 
array analysis depicted a 2.6-fold increase in Tkt expression (table 10), RT-PCR data depicted an 
upregulation of 3.2-fold in fatty rats at 24 days of age, compared to wildtypes (figure 11 ). 
Transketoiase was affected by genotype, age and the genotype by age interaction (table 138). 
Glycerol 3-phosphate acyltransferase (Gpam) catalyzes the initial step in triglyceride and 
phospholipid synthesis converting glycerol 3-phosphate to monoacylglycerol 3-phosphate (54). 
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Table 1 2A. Type 3 tests of fixed effects for fatty acid synthase. 
effect num DF 
geno 1 
age 1 
geno*age 1 
sex 1 
geno*sex 1 
age*sex 1 
geno*age*sex 1 
4 - fatty acid synthase 
/ 
3.5 --' fa/fa 
3 --'  
2.5 --: 
2 --=  
1 .5 -' 
1 _: 
0.5 --' 
0 
20 
days of age 
p<0.0001 
+/+ 
24 
den DF F Value Pr > F 
27 
27 
27 
27 
27 
27 
27 
'iii 
.2: 
8 1 . 1 9  <.0001 
90.26 <.0001 
76 .61  < .0001 
1 4.35 0.0008 
1 8.06 0. 0002 
1 3.3 1  0 .001 1 
1 6. 1 6  0.0004 
1 _2 
_ famesyl diphosphate synthase 
1 -
fa/fa 
0.8 - p<0.0001 
0.6 -
0.4 ...: 
+/+ 
0.2 -
0 
20 24 
days of age 
Figure 1 0. Relative expression of fatty acid synthase and farnesyl diphosphate synthase. At 20 
days of age expression of fatty acid synthase and farnesyl diphosphate synthase is similar 
between fatty and wildtype rats. At 24 days of age the expression of fatty rats is upregulated, 
compared to wildtypes, in both fatty acid synthase and farnesyl diphosphate synthase 
(p<0.0001) .  
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Table 12B. Type 3 tests of fixed effects for farnesyl diphosphate 
synthase. 
effect num DF den DF F Value Pr > F 
gene 1 27 28.81 <.0001 
age 1 27 13.4 0.0011 
gene*age 1 27 13.58 0.0010 
sex 1 27 0.94 0.3420 
gene*sex 1 27 13.49 0.0010 
age*sex 1 27 3.11 0.0891 
gene*age*sex 1 27 9.69 0.0043 
Table 13A. Type 3 tests of fixed effects for malic enzyme. 
effect num DF den DF F Value Pr > F 
gene 1 27 34.81 <.0001 
age 1 27 42.76 <.0001 
geno*age 1 27 28.34 < .0001 
sex 1 27 2.38 0.1342 
geno*sex 1 27 4.68 0.0395 
age*sex 1 27 2.24 0.1462 
geno*age*sex 1 27 5.39 0.0280 
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1 -:  malic enzyme fa/fa 
1 .6 -::  transketolase fa/fa 
0.9 � 1 .4 --: 
0.8 � 
1 .2 --:  C: 
0.7 � .Q 0 -
en "iii 1 --:  en 0.6 � (/) p<0.0001 � 
0.5 � p<0.0001 C. 0.8 --: )( >< 
Q) 
0.4 � 
-� 0.6 --: 0.3 � 1ii 
0 4 --:  
+/+ 
� 0.2 � � 
0. 1  � ) +/+ 0.2 --: 
0 0 
20 24 20 24 
days of age days of age 
Figure 11. Relative expression of malic enzyme and transketolase. At 20 days of age expression 
of fatty malic enzyme and transketolase is similar between fatty and wildtype rats. At 24 days of 
age the expression of fatty rats is upregulated, compared to wildtypes, in both transcripts 
(p<0.0001 ). 
Table 13B. Type 3 tests of fixed effects for transketolase. 
Effect Num DF Den F Value Pr > F 
DF 
geno 1 26 18.2 0.0002 
age 1 26 4.38 0.0464 
geno*age 1 26 8.89 0.0061 
sex 1 26 0.06 0.8057 
geno*sex 1 26 2.33 0.1389 
age*sex 1 26 2.53 0.1239 
geno*age*sex 1 26 2.56 0.1219 
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Gpam is influenced by genotype, age and all genotype interactions (table 14A). At 20 days of 
age Gpam expression in wildtype and fatty rats were not significantly different (figure 12). As with 
other transcripts involved in lipogenic pathways, fatty Gpam expression was upregulated 
compared to wildtypes at 24 days of age (figure 12). At 24 days of age, fatty Gpam expression 
was upregulated 4.9-fold (figure 12). This was similar to the array results with which fatty rats 
experienced a 2.6-fold increase in Gpam expression at 24 days of age compared to wildtypes 
(table 10). 
Insulin induced gene 1 (lnsig1) is a transcriptional regulator involved in cholesterol 
homeostasis and is proposed to "break" lipogenesis (66). While average lnsig1 expression was 
similar between wildtype and fatty rats at 20 days of age, expression in fatty rats was upregulated 
2.3-fold at 24 days of age (figure 12) .  The array results depicted an upregulation of 2. 1-fold in  
fatty rats, compared to wildtypes, at  24 days of age (table 10). lnsig1 was affected by genotype, 
age, genotype by age and genotype by age by sex interactions (table 148). 
Peroxisome proliferator activated-receptor y (PPARy) is a nuclear receptor that regulates 
the expression of genes for glucose utilization and lipogenesis in adipose tissue and is involved in 
adipocyte differentiation (64). Although PPARy was not among the transcripts detected by the 
Genechip, we analyzed PPARy expression because of its role in the regulation of lipogenic 
enzymes. PPARy expression was influenced by genotype, age and sex and by all interactions 
expect age by sex (table 15A). Unlike the transcripts discussed earlier, PPARy expression was 
differentially expressed at both 20 and 24 days of age (figure 13). At 20 days of age, fatty rats 
experienced a 1 .6-fold increase in PPARy expression and at 24 days of age, fatty rats 
experienced a 1.8-fold increase in PPARy expression (figure 13). Because PPARy was not 
present on the Genechip, there is no estimated expression available through the microarray 
results. 
Stearoyl CoA desaturase 1 (Scd1) is a lipogenic enzyme that catalyzes the delta-9-cis 
desaturation of fatty acids, thus forming monounsaturated fatty acids palmitoleate (primarily) and 
oleate(55). Tests of fixed effects showed that stearoyl CoA desaturase 1 was influenced by 
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Table 14A. Type 3 tests of fixed effects for mitochondrial glycerol 3-
phosphate acyltransferase. 
effect num DF den DF F Value Pr > F 
geno 1 27 57. 09 <. 0001 
age 1 27 7.55 0.0106 
geno*age 1 27 38.30 <. 0001 
sex 1 27 0. 39 0.5350 
geno*sex 1 27 8.65 0.0066 
age*sex 1 27 0.21 0.6493 
geno*age*sex 1 27 7 .72 0.0098 
1 .4 glycerol 3-phosphate acyltransferase 
1 .4 --::  insulin induced gene 1 
fa/fa 1 2 � fa/fa 1 .2 
1 �  C: 
·;;; 
·en Cl) 
0.8� p<0.0001 Cl) � � 0.8 
p<0.0001 
Ql 0.6 � Q) 0.6 Q) +/+ Q) > :> � 0.4 ...:: :;:, 0.4 a, T � � 
0.2 +/+ 0.2 � 
0 20 24 
20 24 
days of age days of age 
Figure 12. Relative expression of glycerol 3-phosphate acyltransferase and insulin induced gene 
· 1. Expression of glycerol 3-phosphate acyltransferase and insulin induced gene 1 is similar 
between fatty and wildtype rats at 20 days of age. Both transcripts are upregulated in fatty rats at 
24 days of age, compared to wildtypes (p<0.0001 ). 
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Table 1 48. Type 3 tests of fixed effects for insulin induced gene 1 .  
effect num DF den DF F Value Pr > F 
geno 1 25 14.1 9 0.0009 
age 1 25 22.76 <.0001 
geno*age 1 25 4.1 1 0.0533 
sex 1 25 0.99 0.3293 
geno*sex 1 25 8.65 0.0070 
age*sex 1 25 4.01 0.0562 
geno*age*sex 1 25 9.44 0.0051 
Table 1 5A. Type 3 tests of fixed effects for PPARy. 
effect num OF den DF F Value Pr > F 
geno 1 27 41 .29 <.0001 
age 1 27 6 0.021 0 
geno*age 1 27 7.6 0.01 03 
sex 1 27 4.69 0.0394 
geno*sex 1 27 1 0.27 0.0035 
age*sex 1 27 3.54 0.0709 
geno*age*sex 1 27 1 1 .07 0.0025 
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2 -
1 .8 -:  
1 .6 -:  
1 .4 -:  
1 .2 -:  
1 -= 
0.8 -: 
0.6 -: 
0.4 -: 
0.2 -: 
0 
peroxisome proliferator-activated receptory 
fa/fa 
"iij 
ID 
ID 
20 24 
days of age 
2.5 - stearoyl CoA desaturase 1 
2 -
fa/fa 
1 .5 -
p<0.0001 
1 -
0.5 ...: 
p
<
� 
+/+ 
0 
20 24 
days of age 
Figure 13. Relative expression of peroxisome proliferator-activated receptor y and stearoyl CoA 
desaturase 1. Expression of PPARy and Scd1 in fatty rats at 20 days of age is significant, 
compared to wildtypes (p=0.0211 and p<0.0001, respectively). Additionally, both transcripts are 
upregulated in fatty rats at 24 days of age, compared to wildtypes (p=0.0001 and p<0.0001, 
respectively). 
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genotype, age and by the genotype by age interaction (table 15B). In contrast to other lipogenic 
enzymes discussed above, Scd1 expression was highly induced in fatty rats at both 20 and 24 
days of age (figure 13). At 20 days of age, Scd1 expression was upregulated 10.6-fold in fatty 
rats, compared to wildtypes (figure 13). Scd1 was upregulated to an even greater extent in fatty 
rats at 24 days of age: 5.7-fold compared to wildtypes (figure 13). Because expression increases 
5.4-fold in wildtypes and 2.9-fold in fatty rats with age, Scd1 expression in fatty rats is only 5.7-
fold greater than in wildtypes at 24 days of age. Array results drastically underestimated Scd1 
expression at 20 and 24 days of age, depicting a 6.5-fold (table 9) and 3.2-fold increase (table 
10), respectively. 
Leptin, a hormone secreted from adipose tissue involved in energy homeostasis (59). 
Leptin expression was influenced by genotype, sex and the genotype by age interaction (table 
16A). At 20 days of age fatty rats leptin expression was upregulated 2.3-fold compared to 
wildtypes (figure 14). Fatty rats experienced an even further upregulation of leptin expression at 
24 days of age, 3.5-fold, compared to wildtypes (figure 14). Array results showed an upregulation 
in fatty rats, compared to wildtypes, of 2.8-fold at 20 days of age (table 9), overestimating the 
expression, and 2.5-fold at 24 days of age (table 10), underestimating the expression .  
Lipoprotein lipase (Lpl) is a transcript responsible for the release of free fatty acids from 
triglycerides in circulation and is a regulator of triglyceride deposition (48). Lpl expression was 
influenced by genotype and the genotype by age interaction (table 16B). At 20 days of age Lpl 
expression was upregulated 3.3-fold in fatty rats, compared to wildtype rats (figure 1 4). Fatty Lpl 
expression was upregulated 6.4-fold compared to wildtypes at 24 days of age (figure 14) .  
Moreover, while wildtype rats experienced a reduction in Lpl expression at 24 days of  age, 
compared to 20 days of age, fatty rats experienced an increase from 20 to 24 days of age (figure 
14). 
These data demonstrate that the onset of hyperphagia in fatty rats occurs beiWeen 20 
and 24 days of age. Fatty rats accumulate more adipose mass than witdtypes at 20 and 24 days 
of age, a reflection of the fa mutation. At 20 days of age fatty rats are similar to wildtype rats in 
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Table 1 58. Type 3 tests of fixed effects for stearoyl CoA desaturase 1 .  
effect num OF den OF F Value Pr > F 
geno 1 24 1 79 .59 <.0001 
age 1 24 78.33 <.0001 
geno*age 1 24 37 .02 <.0001 
sex 1 24 0.85 0.3654 
geno*sex 1 24 4.04 0.0544 
age*sex 1 24 0. 1 3  0 .72 1 4  
geno*age*sex 1 24 1 . 1 9  0.2849 
Table 1 6A. Type 3 tests of fixed effects for leptin. 
effect num OF den OF F Value Pr > F 
geno 1 26 44.27 <.0001 
age 1 26 3.2 0.0854 
geno*age 1 26 9.87 0.0042 
sex 1 26 4.98 0.0345 
geno*sex 1 26 0.34 0.5673 
age*sex 1 26 1 .4 0.2476 
geno*age*sex 1 26 0.02 0.893 1  
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4 .5  � fa/fa 2.5 - lipoprotein lipase 
4 �  fa/fa 
C: 3.5 � 2 -=  
'iii 3 � p<0.0001 ,Q 
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V) 1 . 5 ..: 
2 X p<0.0001 
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1 -= � 1 .5 p=0.0238 Q) p<0.0001 m +/+ � � � l 0.5 0 .5 - 1 0 +/+ 
20 24 0 
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Figure 14. Relative expression of leptin and l ipoprotein lipase. Leptin and l ipoprotein lipase 
expression are upregulated in fatty rats, compared to wildtypes, at both 20 {p=0.0238 and 
p<0.0001, respectively) and 24 days of age {p<0.0001 ). 
Table 16B. Type 3 tests of fixed effects for lipoprotein lipase. 
effect num DF den OF F Value Pr > F 
geno 1 24 125.88 <.0001 
age 1 24 1.31 0 .2638 
geno*age 1 24 11.32 0.0026 
sex 1 24 2.09 0.1613 
geno*sex 1 24 0.06 0.8033 
age*sex 1 24 0.21 0.6519 
geno*age*sex 1 24 2.53 0.1248 
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weight and food intake, as demonstrated through their stomach contents. However, by 24 days 
of age fatty rats weigh significantly more than wildtype rats. Additionally, daily gain is significant 
in fatty rats at 24 days of age, compared to wildtypes. Liver weight is the same in animals at 20 
days of age, but is significantly greater in fatty rats by 24 days of age. This weight gain, 
increased stomach contents and increased liver mass can all be attributed to the onset of 
hyperphagia. 
When considering the transcripts fatty acid synthase, malic enzyme, transketolase, 
glycerol 3-phosphate acyltransferase, farnesyl diphosphate synthase and insulin induced gene 1, 
expression was similar in wildtypes and fatty rats prior to the onset of hyperphagia, but 
upregulated in fatty rats after the onset of hyperphagia. However, expression of leptin, stearoyl 
CoA desaturase 1, lipoprotein lipase, and to a lesser extent peroxisome proliferator-activated 
receptor y, was upregulated before and after the onset of hyperphagia in fatty rats (compared to 
wildtype rats). 
DISCUSSION 
The most striking feature of this analysis is the changes in expression of transcripts 
associated with lipogenesis before and after the onset of hyperphagia. The lipogenic enzymes 
fatty acid synthase, malic enzyme, and glycerol 3-phosphate acyltransferase are expressed at 
similar levels in wildtype and fatty rats at 20 days of age. The enzyme farnesyl diphosphate 
synthase, which is involved in cholesterol synthesis (57) , is also expressed at similar levels in 
wildtype and fatty rats at 20 days of age. Transketolase, which is involved in the pentose 
phosphate pathway (49), a source of NADPH for lipogenesis, is also expressed at similar levels 
between wildtype and fatty rats at 20 days of age. These data suggest that lipogenic pathways 
do not contribute significantly to the fatty phenotype before the onset of hyperphagia. However, 
each of these transcripts are upregulated in fatty rats after the onset of hyperphagia; suggesting 
that the development of hyperphagia and increased lipogenesis are tightly linked. 
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The onset of hyperphagia is associated with increased insulin levels (74) .  Insulin 
stimulates lipogenesis by increasing transcription of lipogenic enzymes through the transcription 
factor SREBP-1c. SREBP-1c is tethered to the endoplasmic reticulum by insig1 ; insulin causes 
SREBP-1c to be cleaved off and transported to the nucleus to bind to the promoter region of 
genes for lipogenesis and cholesterol synthesis (95). Although lnsig1 is stimulated by insulin, its 
functional role actually appears to counter the effects of insulin on lipogenesis. Selective 
overexpression of lnsig1 in livers of fatty rats actually inhibits lipogenesis in fatty rats (66). Thus, 
the induction of lnsig1 after the onset of hyperphagia might be a mechanism to maintain control of 
accelerated lipogenesis: 
PPARy is also upregulated after the onset of hyperphagia. PPARy is a nuclear receptor 
that upregulates genes for lipogenesis, including lnsig1 (96). The PPARy activator rosiglitazone 
stimulates lipogenesis in type II diabetes (97). As a result, rosiglitazone increases insulin 
sensitivity (63). Work in this lab has shown that fatties are insulin resistant before the onset of 
hyperphagia and become insulin sensitive after the onset of hyperphagia (90). This suggests that 
the onset of hyperphagia is closely linked with changes in insulin sensitivity. In the current study, 
PPARy was also slightly upregulated in fatty rats prior to the onset of hyperphagia. However, 
Durham (2004) has shown that PPARy protein expression is low prior to the onset of 
hyperphagia, and increases substantially with the development of hyperphagia. In fact, PPARy 
protein level increase in lean littermates of fatty rats over the same interval (90). These 
observations suggest that developmental changes in PPARy signaling may be critical for the 
development of hyperphagia in fatty rats. 
Leptin was upregulated before the onset of hyperphagia and was further upregulated 
after the onset of hyperphagia. These results are consistent with the fact that leptin and the leptin 
receptor normally contribute a feedback loop that maintains adipose mass (58). Because the 
fatty mutation disrupts the signaling abilities of the leptin receptor, leptin expression remains high 
(71 ). Truett et al. (2000) have shown the circulating leptin levels are high before the onset of 
hyperphagia and increase further afterward (74). 
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Lipoprotein lipase was also upregulated before and after the onset of hyperphagia. In 
addition to its roles in delivering fatty acids from the circulation to adipose tissue, lipoprotein 
lipase is an early marker of adipocyte differentiation, increasing in expression before significant 
lipid stores are detectable in preparation for lipid filling (98). The early increase in lipoprotein 
lipase might represent a direct effect of the lack of leptin signaling. However, Ramsay (2003) has 
shown that leptin suppresses lipogenesis without affecting lipoprotein lipase expression (99). 
Instead, leptin may have an indirect effect on lipoprotein lipase expression by inhibiting adipocyte 
d ifferentiation. In this case, the elevation of Lpl in fatty rats would represent the lack of inhibition 
of adipocyte differentiation. 
Stearoyl CoA desaturase 1 was the transcript that was most strongly influenced by fatty 
genotype. Scd1 was upregulated in fatties prior to the onset of hyperphagia and was further 
upregulated after the onset of hyperphagia. Although Scd1 can be considered to be a lipogenic 
enzyme because of its role in forming monounsaturated fatty acids (56), it may be performing a 
d ifferent role prior to the onset of hyperphagia. Cohen et al. (2002) pair-fed ob/ob mice to match 
the intake of leptinized ob/ob mice, then identified d ifferentially expressed genes in liver. Scd1 
was the gene with the largest differences between these two. They suggested that Scd1 may 
play an important role in mediating leptin's effects on energy expenditure, independent of food 
intake. Furthermore, they also crossed Scd1 deficient mice with obi+ mice to produce double 
mutants that were leaner than ob/ob mice (1 00). These data suggest that Scd1 is a major 
mediator of leptin signaling. Asilmaz et al. (2004) showed that Scd1 is an important mediator of 
leptin 's effects on glucose and lipid metabolism in a model of lipodystrophy that lacks expression 
of SREBP1 c in adipose tissue. These mice develop fatty livers and are diabetic. Leptin injected 
into the central nervous system inhibited Scd1 and improved glucose homeostasis in these mice 
( 1 01 ). 
While the mechanisms of action of Scd1 in mediating the effects of leptin on metabolism 
are unknown, it is possible that Scd1 generates an intracellular lipid that acts as a signaling 
molecule ( 1 02). This signaling molecule could be a ligand for PPARy or other lipid binding 
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nuclear receptors. The onset of hyperphagia in fatty rats could be dependent of the interaction of 
this signal with developmentally regulated PPARy. 
This project has identified a set of major regulators that are proposed to work together to 
regulate the onset of hyperphagia in fatty rats and drive the induction of lipogenesis. One 
hypothesis is that these changes in metabolism lead to an induction in lipogenesis and secondary 
hyperphagia. An alternative explanation might be that a central mechanism activates 
hyperphagia, and lipogenesis is upregulated in response. Because rosiglitazone can stimulate 
the development of hyperphagia by inducing lipogenesis, we favor the first alternative. This 
hypothesis may be testable by treating young fatty rats with rosiglitazone to promote and earlier 
onset of hyperphagia. 
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APPENDIX ,A1 : DETAILED METHODS 
RNA Extraction Protocol by Totally RNA kit (Ambion Inc., Austin, TX) 
Day 1:  
1. Homogenize frozen adipose tissue in 30 ml Oak Ridge tube with 5 ml Denaturation 
Solution. 
2. Add 5 ml Chloroform and mix thoroughly to extract excess lipids. 
3. Centrifuge at 10,000 to 12,000 x g at 7°C for 20 minutes. 
4. Transfer upper aqueous phase to a new vessel. 
5. Add 5 ml Chloroform and mix thoroughly. 
6. Centrifuge at 10, 000 to 12,000 x g at 7°C for 20 minutes. 
7. Transfer upper aqueous phase to a new vessel. 
8. Transfer 5 ml of Phenol:Chloroform: IAA solution to homogenate and mix. 
9. Store preparation in ice bath for 15 minutes. 
10. Centrifuge at 10,000 to 12,000 x g at 7°C for 30 minutes. 
1 1 . Transfer upper aqueous phase and white interface to a new vessel. 
12. Centrifuge at 10, 000 to 12,000 x g at 7°C for 5 minutes. 
13. Transfer upper aqueous phase to a new vessel. 
14. Add 1/10 of volume of step 13 of Sodium Acetate Solution and mix. 
15. Transfer 5 ml of Acid-Phenol:Chloroform solution to homogenate and mix. 
16. Store preparation in ice bath for 15 minutes. 
17. Centrifuge at 10 ,000 to 12,000 x g at 7°C for 30 minutes. 
1 8. Transfer upper aqueous phase and white interface to a new vessel. 
19. Centrifuge at 10,000 to 12,000 x g at 7°C for 5 minutes. 
20. Transfer upper aqueous phase to an RNase-free vessel avoiding transfer of interface. 
21. Add an equal volume of step 20 of isopropanol (stored at 4°C) and mix. 
22. Store preparation overnight at -20°C to allow RNA to precipitate. 
Day 2: 
1. Centrifuge at 10,000 to 12,000 x g at 7°C for 30 minutes. 
2. Remove and discard supernatant solution. 
3. Re-suspend pellet in 300 µL DEPC H2O and dissolve pellet in hot water bath with 
intermittent vortexing. 
4. Add 1 50 µL of 0.5M LiCI Precipitation Solution to the preparation and mix. This step 
removes excess carbohydrates and small RNA molecules. 
93 
5. Store preparation at -20°C for 30 minutes. 
6. Centrifuge at 10,000 to 12,000 x g at 7°C for 30 minutes. 
7. Remove supernatant and add 300 µL of room temperature 70% ethanol prepared 
with nuclease free water to wash pellet. 
8. Dislodge pellet by flicking tube and gently agitate for 1 minute. 
9. Centrifuge at 3,000 x g at 4°C for 20 minutes. 
10. Remove ethanol supernatant thoroughly and allow pellet to dry completely under 
fume hood. 
11. Re-suspend pellet in 300 µL DEPC H2O/ 0.1 mM EDT A Store RNA at -80°C for long 
term or at -20° C for short-term. 
Quantification of RNA 
1. Prepare 1 mM Na2HPO4 , pH 8.5 by mixing 0.14196 grams Na2HPO4 with 1 L 
deionized H2O. 
2. Load 500 11L 1 mM Na2HPO4, pH 8.5 in 1.5 ml eppendorf tube for each sample to be 
quantified plus one additional tube to be used as the blank. 
3. Load 5 µL of unknown RNA samples in the eppendorf tubes, skipping the tube to be 
used as the blank. 
4.  Quantify with use of Spectrophotometer reading each RNA sample at both 260 nm 
and 280 nm. 
Denaturing gel electrophoresis 
Preparation of 1 OX MOPS buffer 
1. Weigh 41.90 g of MOPS, pH 7.0 (final concentration = 0.2 M). 
2. Weigh 4.70 g of EDTA, pH 8.0 (final concentration = 10mM). 
3 .  Weigh 4.10 g of sodium acetate (final concentration = 50mM). 
4. Mix MOPS, EDTA and sodium acetate in 1 liter DEPC treated water. 
5. Insure a pH of 7.0. 
Preparation of 1 % agarose gel 
1. Prepare a 1.2% to 1.5% LE agarose gel in a volume of 100 ml. 
2. Weigh 1.2-1.5 g agarose. 
3. Mix agarose with 80 ml DEPC water in a baked flask. 
4. Microwave until all agarose is cooked (about 3 minutes) 
5. Cool gel solution to 50° C in water bath. 
6. Add 10 ml 10X MOPS buffer (final concentration = 1X) to gel solution. 
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7. Add 1. 79 ml formaldehyde and mix (final concentration == 0.22M). · 
8. Add 5 µI EtBr and mix thoroughly. 
9. Keep the gel solution at 50° C until ready to pour. 
10. Carefully pour the gel into the gel tray trying to minimize bubbles and immediately add gel 
combs. 
11 . Allow gel to cool about 20-30 minutes before loading samples. 
Preparation of 1 X MOPS I 0. 22M formaldehyde running buffer 
1. Mix 70 ml 10X MOPS, 12.5 ml formaldehyde and 617.5 ml DEPC treated water. 
2. Add runn ing buffer to completely solidified and cooled gel until running buffer covers the 
gel by about 3-4 mm. 
Preparation of samples to load on gel 
1. Samples will be diluted to a final volume of 20 µI. 
2. Add 10 µI of formaldehyde loading buffer. 
3. Calculate the volume of sample necessary for 2-3 Dg of RNA per well and add this to a 
sterile 1.5 ml tube. 
4.  Add DEPC water to make the final volume 20 µI. 
5. Heat samples 10 minutes at 65 degrees. 
6. Load 20 µI of prepared samples. 
7. Run gel at 75 volts for 3-4 hours. 
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Quantitative Real-Time Polymerase Chain Reaction 
Preparing the Smart Cycler 
1. Turn on computer. 
2. Turn on PCR machine(s). 
3. Double click on "Smart Cycler'' icon. 
4. Select "Create Run." 
5. Label run name: (lnitials)(Date)(Target). 
6 .  Select "Add Remove Sites" - select run protocol "Truett1" and select sites A1 -. . .  for 
corresponding numbers of samples to run and select "OK." 
7. Select sample type for each site labeling the standards as "STD" and the unknowns 
as "UNKN." 
8. Assign concentrations for the standards in the "FAM Std CONC" column. 
9. Assign sample id's in the "Sample ID" column 
10. Prepare samples for quantification. 
Preparation of RNA dilution curve 
1. Dilute concentration of RNA sample with high levels of targets expression to 50 ng/µI. 
2. Perform serial dilutions to generate 6 RNA concentrations from which a dilution curve 
will be developed. The concentration will range from 0.2441 40625 to 50 ng/µI (table 
20). 
3. Add 5 µI of dilution ID's #1 -6 to the first 6 Cepheid Smart Cycler reaction tubes. 
4. Add 5 µI of unknown RNA samples to reaction tubes #7-(32). 
Preparation of master mix 
1. Prepare the PCR mix (master mix). Be sure to add primers and probe and 
subsequent reagents in dim light (table 21 ). 
2. Add 20 µI of master mix to each of the reaction tubes. 
Running the Cepheid Smart Cycler 
1. Centrifuge reaction tubes thoroughly and check that no bubbles are visible. 
2. Carefully insert reaction tubes into corresponding wells of PCR machine, avoid 
touching the optical excitation/detection window. 
3 .  Close lids of PCR machine and select "Start Run" - the PCR Machine will run for 
about 2 hours. 
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Table 1 7. RNA serial dilutions to prepare dilution curve. 
dilution ID concentration RNA(µI) DEPC H20 ng RNA per reaction 
(ng/µI) (µI) (when used in 5 µI volume) 
# 1  50 0 0 250 
#2 1 2.5 25 µI of #1 75 62.5 
#3 3.1 25 25 µI of #2 75 1 5.625 
#4 0.781 25 25 µI of #3 75 3.90625 
#5 0.1 9531 25 25 µI of #4 75 0.9765625 
#-6 0.0488281 25 25 µI of #5 75 0 .2441 40625 
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Table 18. Preparation of master mix. 
reagent 
DEPC Water 
10X Taqman Buffer A from Taqman Gold Kit 
MgCl2, 25 mM GeneAmp kit 
dATP, 10 mM GeneAmp kit 
dCTP, 10 mM GeneAmp kit 
dGTP, 10 mM GeneAmp kit 
dTTP, 10 mM GeneAmp kit 
20X Applied Biosystems Assays on Demand 
primers and probes 
Mul V Reverse transcriptase, 50 U/ml GeneAmp kit 
RNase inhibitor, 20 U/ml GeneAmp kit 
AmpliTaq Gold from Taqman Gold kit 
Total 
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µI per reaction 
7.350 
2.5 
5.5 
0.75 
0.75 
0.75 
0.75 
1.25 
0.125 
0.125 
0.15 
7.350 
µI per 32 reactions 
(with 20% excess) 
282. 240 
96.000 
211.200 
28.800 
28.800 
28.800 
28.800 
48.000 
4 .800 
4.800 
5.760 
768.000 
A
P
P
EN
D
IX
 A
2. SA
S DA
TA
 
T
able 19. P
hysical traits of w
ildtype and fatty rats at 20 and 24 days of age. 
w
eig
ht in gram
s 
id 
lit 
genotype 
body 
gain 
liver 
inguinal 
stom
ach 
em
pty 
stom
ach 
age 
sex 
stom
ach 
contents 
12380 
1142
 
24 
0 
F 
45.71 
2.87 
1.630 
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0.267 
12381 
1142
 
24 
2 
F 
48.97 
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0.706 
1.048 
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0.950 
0.402 
0.672 
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0.162 
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0.299 
0.64
1 
1.061 
0.467 
12646 
12.745 
0.084 
0.438 
0.433 
0.279 
0.501 
0.162 
0.017 
0.300 
1.139 
0.242 
12651 
31.432 
2.825 
1.491 
1.018 
0.011 
0.166 
0.025 
0.175 
12652 
21.214 
0.193 
1.170 
0.364 
0.103 
0.641 
0.151 
0.346 
0.2
13 
0.022 
0.394 
12662 
24.695 
0.248 
0.682 
0.477 
0.128 
0.974 
0.241 
0.580 
0.488 
0.369 
0.347 
12665 
24.804 
2.134 
1.122 
1.918 
0.770 
7.594 
0.797 
1.262 
1.485 
0.401
 
1.415 
12675 
17.058 
0.378 
0.505 
0.735 
0.201 
3.980 
0.333 
0.072 
0.646 
1.519 
12676 
22.566 
1.761 
0.523 
2.240 
1.002 
8.537 
0.797 
0.449 
0.985 
0
.459 
0.861 
APPENDIX A3. STATISTICAL ANALYSIS 
SAS Program Code 
Program 
opt ions  l i ne s i ze 7 2 ; options pages i z e  2 0 00 0 ;  
opt ions nodat e ;  opt i on s  nonurnber ; run ; 
data one ;  
i n f i l e  ' i : /Ma r y / swi t chdata . txt ' FIRSTOBS=2 ;  
i nput i d  l i t  a g e  geno s ex $ body gain l iver ing s t om MT cont ent s r l 8 s  
f a s  pparg S c d l  M e l  Lep Gpam T kt Fdps Insigl  Lpl ;  
run ;  
%macro mixed ( yvar ) ; 
proc mixed ; 
c l a s s  id l i t  geno age s e x ;  
model & yvar=geno l age l s ex ;  
random l i t ;  
l smeans geno�age / s l i ce=age s l i ce=geno ; 
run ;  
%mend mixed;  
%mixed ( body ) ; %mixed ( gain ) ; %mixed ( l iver ) ; %mixed ( in g )  ; %mixed 
( st om ) ; %mixed (MT ) ; %mixed ( content s ) ; %mi xed ( rl 8 s ) ; 
%mixed ( fa s ) ; %mixed ( pparg ) ; %mixed ( Scdl ) ; %mixed ( Me l ) ; %mixed ( Lep ) ; 
%mixed ( Gpam ) ; %mixed ( Tkt ) ; 
%mixed ( Fdps ) ;  %mixed ( In s i gl ) ; %mixed ( Lpl ) ; 
1 02 
SAS LOG 
Log 
3 5  opt1 ons l i nes i ze 72 ; opti ons pagesi ze 
36 opti ons nodate ; opt i ons nonumbe r ;  run ; 
37  data one ;  
3 8  i nfi l e  ' i : /Mary/swi tchdata . txt ' FIRSTOBS=2 ; 
20000 ; 
39 i nput id l i t  age geno sex $ body gai n l i ver i ng stom MT contents 
39 r18s fas pparg Scdl Mel Lep Gpam Tkt Fdps Ins i gl Lpl ; 
40 run ; 
NOTE : The i nfi l e  ' i : /Mary/swi tchdata . txt ' i s :  
Fi l e  Name=i : \Mary\swi tchdata . txt , 
RECFM=V , LRECL=2 5 6  
NOTE : 4 5  records were read from the i nfi l e  ' i : /Mary/swi tchdata . txt ' . 
The mi n i mum record l ength was 166 . 
The maxi mum record l ength was 197 . 
NOTE : The data set WORK . ONE has 45 observati ons and 24  vari abl es . 
NOTE : DATA statement used (Total p rocess ti me) : 
real ti me 0 . 09 seconds 
cpu t i me 0 . 01 seconds 
41 %macro mi xed (yvar) ; 
42 p roc mi xed ; 
43 cl ass id l i t  geno age sex ; 
44 model &yvar=geno l age l sex ; 
4 5  random l i t ; 
46 l smeans geno*age /sl i ce=age sl i ce=geno ; 
47 run ; 
48 %mend mi xed ; 
49 %mi xed ( body) ;%mi xed (gai n) ;%mi xed (l i ver) ; %mi xed ( i ng) ; %mi xed (stom) ; 
49 ! %mi xed (MT) ; %mi xed (contents) ; %mi xed ( r18s) ; 
NOTE : convergence cri ter ia  met . 
NOTE : PROCEDURE MIXED used (Total process time) : 
real ti me 0 . 94 seconds 
cpu t i me 0 . 07 seconds 
NOTE : Convergence cri te r ia  met . 
NOTE : PROCEDURE MIXED u sed (Total p rocess time) : 
real t i me 0 . 07 seconds 
cpu t i me 0 . 07 seconds 
NOTE : convergence cri teri a met . 
NOTE : PROCEDURE MIXED used (Total process ti me) : 
real ti me 0 . 08 seconds 
cpu ti me 0 . 06 seconds 
NOTE : Convergence c ri ter ia  met . 
NOTE : PROCEDURE MIXED used (Total process t ime) : 
real ti me 0 . 07 seconds 
cpu ti me 0 . 06 seconds 
NOTE : convergence cri teri a met . 
NOTE : PROCEDURE MIXED used (Total process ti me) : 
real time 0 . 09 seconds 
cpu t i me 0 . 08 seconds 
NOTE :  convergence c ri teri a met . 
NOTE : PROCEDURE MIXED used (Total process time) : 
real ti me 0 . 08 seconds 
cpu t i me 0 . 08 seconds 
NOTE : convergence c ri ter ia  met . 
NOTE : PROCEDURE MIXED used (Total process ti me) : 
real time 0 . 08 seconds 
cpu t i me 0 . 08 seconds 
NOTE : convergence cri teri a met . 
NOTE : PROCEDURE MIXED used (Total p rocess time) : 
real t i me 0 . 09 seconds 
cpu ti me 0 . 08 seconds 
50 %mi xed (fas) ; %mi xed (pparg) ;%mi xed (Scd1) ;%mi xed (Mel) ; 
50 %mi xed ( Lep) ; %mi xed (Gpam) ; %mi xed (Tkt) ; 
NOTE : convergence cri teri a met . 
NOTE : PROCEDURE MIXED used (Total process ti me) : 
NOTE : 
NOTE : 
NOTE : 
real t i me 0 . 14 seconds-
cpu t i me 0 . 06 seconds 
Convergence cri teri a met . 
Esti mated G matr i x  i s  not pos it ive defi n i te .  
PROCEDURE MIXED used (Total p rocess ti me) : 
real ti me 0 . 08 seconds 
cpu ti me 0 . 06 seconds 
NOTE : convergence cri teri a met . 
NOTE : PROCEDURE MIXED used (Total process t ime) : 
real t i me 0 . 07 seconds 
cpu t i me 0 . 06 seconds 
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NOTE : convergence  cri te ri a met . 
NOTE : PROCEDURE  MIXED used (Total p rocess ti me) : 
NOTE : 
NOTE : 
NOTE : 
NOTE : 
NOTE : 
NOTE : 
real t ime 0 . 08 seconds 
cpu t ime 0 . 06 seconds 
Convergenc e  cr i teri a met . 
Estimated G matri x i s  not pos i ti ve defi ni te .  
PROCEDURE MIXED u sed (Total p rocess ti me) : 
real ti me 0 . 07 seconds 
cpu ti me 0 . 06 seconds 
1 observati on i s  not i ncl uded because of mi ssi ng val ues . 
convergence cr i teri a met . 
PROCEDURE MIXED used (Total process t ime) : 
real t ime 0 . 07 seconds 
cpu ti me 0 . 06 seconds 
NOTE : Convergence cri teri a met . 
NOTE : PROCEDURE MIXED used (Total process t ime) : 
real t ime 0 . 08 seconds 
NOTE : 
NOTE : 
NOTE : 
cpu ti me 0 . 07 seconds 
1 observati on i s  not i ncl uded because  of mi ssi ng val ues . 
convergence cr iteri a met . 
PROCEDURE MIXED used (Total process ti me) : 
real t ime 0 . 07 seconds 
cpu t ime 0 . 07 seconds 
51  %mi xed (Fdps) ; %mi xed (Insi gl) ; %mi xed (Lpl ) ;  
NOTE : convergence cr iteri a met . 
NOTE : PROCEDURE MIXED used (Total process ti me) : 
NOTE 
NOTE 
NOTE 
NOTE 
NOTE 
NOTE 
NOTE 
real t ime 0 . 18 seconds 
cpu t ime 0 . 07 seconds 
2 observati ons are not i ncl uded because of mi ssi ng val ues . 
convergence c ri teri a met . 
Estimated G matri x i s  not posi t ive defi ni te .  
PROCEDURE MIXED used (Total p rocess ti me) : 
real time 0 . 08 seconds 
cpu t ime 0 . 06 seconds 
3 observati ons are not i ncl uded because of mi ssi ng val ues . 
convergence cri teri a met . 
PROCEDURE MIXED used (Total process ti me) : 
real t ime 0 . 07 seconds 
cpu t ime 0 . 06 seconds 
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Output 
SAS Output 
Data Set 
The SAS system 
The Mi xed P rocedure 
Model Informat ion 
WORK . ONE 
Dependent vari abl e 
covari ance Structure 
Estimati on Method 
Resi dual vari ance Method 
Fi xed Effects SE Method 
Degrees of F reedom Method 
body ( body wei ght , grams) 
vari ance Components 
cl ass 
i d  
1 i t  
geno 
age 
sex 
cl ass 
Level s 
45 
12 
2 
2 
2 
REML 
Profi l e  
Model -Based 
contai nment 
Level Information 
val ues 
12380 12381 12382 12383 12384 
12385 12418 12419 12420 12421 
12423 1242 5  12427 12428 12478 
12485 12487 12492 12494 12495 
12498 12499 12504 12506 12507 
12509 12511 12513 12 514 12554 
12 557  12611 12614 12616 12617 
12618 12639 12641 12646 12651 
12652 12662 12665 12675 12676 
1142 1146 1150 1151 1152 115 3 
1157 1162 1164 1165 1166 1167 
0 2 
20 24 
F M 
Dimensi ons 
covari ance Parameters 
col umns i n  x 
2 
27  
12 
1 
45  
col umns in  z 
Subj ects 
Max obs Per subj ect 
Number of observati ons 
Number of observati ons Read 
Number of observati ons used 
Number of obse rvati ons Not used 
45  
45 
0 
Iterati on 
0 
1 
2 
3 
4 
5 
Effect 
geno 
age 
Iterati on 
Eval uati ons -2 
1 
3 
2 
1 
1 
1 
Hi story 
Res Log Li ke 
199 . 28107931 
17 5 . 33458031 
174 . 962012 5 5  
174 . 79484295 
174 . 78202153  
174 . 78191096 
convergence cri teri a met . 
covar i ance Parameter 
Esti mates 
Cov Parm Esti mate 
l i t  6 . 2425 
Resi dual 2 . 6 546 
Fi t Stati sti cs 
-2 Res Lo1 Li kel i hood AIC ( smal er i s  better) 
AICC ( smal l e r  is better) 
BIC ( smal l e r is better) 
174 . 8  
178 . 8  
179 . 1  
179 . 8  
Type 3 Tests of Fi xed Effects 
Num Den 
DF DF F Val ue 
1 2 7  7 . 41 
1 2 7  99 . 79 
geno*age 1 2 7  14 . 06 
sex 1 2 7  11 . 94 
geno*sex 1 2 7  0 . 17 
age*sex 1 27  0 . 15 
geno*age*sex 1 2 7  0 . 91 
Least Squares Means 
1 05 
cri teri on 
0 . 02032755  
0 . 00270359 
0 . 00022675 
0 . 00000206 
0 . 00000000 
Pr > F 
0 . 0112 
< . 0001 
0 . 0009 
0 . 0018 
0 . 6818 
0 . 7026 
0 . 3489 
Standard 
Effect gen o  �ge Esti mate Error DF t val ue Pr > l t l  geno*age 3 5 . 3427 1 .  2478 27  28 . 32 < . 0001 
geno*age 0 24 49 . 3127 1 . 0958 27 4 5  . 00 < . 0001 
geno*age 2 20  34 . 8341 1. 2377 27  28 . 14 < . 0001 
geno*age 2 24 5 2 . 5145 1 . 1042 2 7  4 7 .  56  < . 0001 
Tests of Effect sl i ces 
Num Den 
Effect geno �ge DF DF F val ue Pr > F geno*age 1 27  0 . 47 0 . 4982 
geno*age 24 1 27 23 . 8 3  < . 0001 
geno*age 0 1 27  70 . 77  < . 0001 
geno*age 2 1 27  113 . 6 3  < . 0001 
1 06 
Dependent vari abl e gai n (dai l y  gai n on the l ast day of l i fe ,  g rams) 
Iterati on 
0 
1 
2 
Effect 
geno 
age 
Iterati on Hi story 
Eval uati ons -2  
1 
2 
1 
Res Log Li ke 
77 . 62838352 
77 . 3 3088728 
77 . 33088041 
convergence cri teri a met . 
covari ance Parameter 
Esti mates 
cov Parm Esti mate 
l i t  0 . 02880 
Resi dual 0 . 3053 
Fit Stati sti cs 
- 2  Res LoT Li kel i hood AIC (smal er i s  better) 
AICC ( smal l er i s  better) 
BIC (smal l er i s  better) 
Type 3 Tests of Fi xed Effects 
Num Den 
OF OF F val ue 
1 2 7  o .  2 3  
1 27  68 . 31 
geno*age 1 2 7  19 . 78 
sex 1 2 7  2 . 26 
geno*sex 1 2 7  0 . 05 
age*sex 1 2 7  0 . 02 
geno*age*sex 1 2 7  0 . 05 
Least squares Means 
Standard 
Effect geno age Esti mate Error OF 
geno*age 0 20 2 . 1973 0 . 1930 2 7  
geno*age 0 24 3 . 1019 0 . 1713 27 
geno*age 2 20 1 .  5 374 0 . 1917 27  
geno*age 2 24  3 . 9218 0 . 1766 2 7  
Tests of Effect sl i ces 
Num Den 
7 7 .  3 
8 1 .  3 
81 . 7  
82 . 3  
t 
cri ter ion 
0 . 00000147 
0 . 00000000 
Pr > F 
0 . 6345  
< . 0001 
0 . 0001 
0 . 1441 
0 . 8201 
0 . 8924 
0 . 8196 
val ue Pr > I t I 
11 . 38 < . 0001 
18 . 11 < . 0001 
8 . 02 < . 0001 
22 . 21 < . 0001 
Effect geno 
25
e OF OF F val ue P r  > F 
geno*age 1 27  7 . 08 0 .  0130 
geno*age 24 1 27  13 . 67 0 . 0010 
geno*age 0 1 27  12 . 29 0 . 0016 
geno*age 2 1 27 83 . 68 < . 0001 
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Dependent vari abl e l i ve r  (l iver  wei ght , g rams) 
Iterati on Hi story 
Iterati on 
0 
1 
2 
3 
Eval uati ons - 2  
1 
3 
1 
1 
Res Log Li ke 
11 . 18038481 
6 . 0165912 5 
6 . 00295648 
6 . 00281297 
Effect 
geno*age 
geno*age 
geno*age 
geno*age 
convergence cri teri a met .  
covari ance Parameter 
Esti mates 
cov Parm Esti mate 
l i t  0 . 01754 
Resi dual 0 . 03791 
Fit Stati sti cs 
-2 Res Log Li kel i hood 
AIC (smal ler i s  better) 
AICC (smal l er is better) 
BIC (smal l e r  i s  better) 
Type 
Effect 
3 Tests 
Num 
OF 
1 
1 
1 
1 
1 
1 
1 
of Fi xed 
Den 
OF 
27  
27  
2 7  
2 7  
2 7  
2 7  
2 7  
Effects 
F val ue 
17 . 37 
76 . 98 
15 . 5 1  
13 . 93 
geno 
age 
geno*age 
sex 
geno*sex 
age*sex 
geno*age*sex 
geno �ge 
0 24 
2 20  
2 24 
2 . 03 
0 . 00 
0 . 24 
Least squares Means 
standard 
Esti mate Error OF 
1 . 1572  0 . 08750 2 7  
1 . 8174 0 . 07829 27 
1 . 1708 0 . 08634 2 7  
2 . 2947 0 . 07981 27 
Tests of Effect sl i ces 
Num Den 
6 . 0  
10 . 0  
10 . 4  
11 . 0  
C ri te ri on 
0 . 00041316 
0 . 00000459 
0 . 00000000 
Pr > F 
0 . 0003 
< . 0001 
0 . 0005 
0 . 0009 
0 . 1653 
0 . 9746 
0 . 62 59 
t val ue Pr > ! t i  
13 . 23 < . 0001 
2 3 . 21 < . 0001 
1 3 .  56 < . 0001 
28 . 7 5 < . 0001 
Effect geno age OF OF F val ue Pr  > F 
geno*age 20 1 2 7  0 . 02 0 . 8789 
geno*age 24 1 27  37 . 19 < . 0001 
geno*age 0 1 2 7  31 . 62 < . 0001 
geno*age 2 1 2 7  91 . 38 < . 0001 
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Effect 
Dependent var i abl e i ng (i ngui nal adi pose pads wei ght , g rams) 
Iterati on 
0 
1 
2 
3 
4 
5 
Effect 
geno 
age 
Iterati on 
Eval uati ons - 2  
1 
2 
1 
1 
1 
1 
Hi story 
Res Log Li ke 
- 2 1 .  34400323 
-27 . 59817381 
-27 . 92 5 5 3852  
-27 . 96699643 
-27 . 968004 58 
- 2 7 . 96800537 
Convergence cri ter ia  met . 
covari ance Parameter 
Esti mates 
cov Parm Esti mate 
l i t  0 . 01346 
Resi dual 0 . 01323 
Fi t Stati sti cs 
-2 Res Lo� Li kel i hood Arc (smal er i s  better) 
AICC ( smal l er i s  better) 
BIC (smal l er i s  better) 
- 28 . 0  
-24 . 0  
- 2 3 . 6  
- 2 3 . 0  
Type 3 Tests of Fixed Effects 
Num Den 
DF DF F val ue 
1 27  283 . 5 3 
1 27  34 . 19 
geno''age 1 2 7  12 . 60 
s ex 1 27  0 . 5 3  
geno*sex 1 27 0 . 58 
age*sex 1 27  0 . 08 
geno*age*sex 1 27 0 . 00 
Least squares Means 
Standard 
geno age Esti mate E rror DF t 
cr i ter i on 
0 . 00 57 5461 
0 . 00078918 
0 . 00002063 
0 . 00000002 
0 . 00000000 
Pr > F 
< . 0001 
< . 0001 
0 . 0014 
0 . 472 5  
0 . 4 5 30 
0 .  7740 
0 . 9830 
val ue P r > i t I 
geno*age 0 20 0 . 2997 0 . 06472 2 7  4 . 63 < . 0001 
0 24 0 . 05764 geno*age 0 . 6397 27  11 . 10 < . 0001 
geno*age 2 20 0 . 7630 0 . 06394 27  11 . 93 < . 0001 
geno*age 2 24 1. 3 505  0 . 05839 27 2 3 . 13 < . 0001 
Tests of Effect sl i ces 
Num Den 
Effect geno age DF DF F val ue Pr  > F 
geno*age 20 1 2 7  78 . 90 < . 0001 
geno*age 24 1 27  2 3 5 . 93 < . 0001 
geno*age 0 1 27  15 . 39 0 . 0005 
geno*age 2 1 27  46 . 03 < . 0001 
1 09 
Dependent vari abl e stom (ful l stomach wei ght , g rams) 
Iterati on Hi story 
Iterati on 
0 
1 
2 
3 
Eval uati ons - 2  
1 
2 
1 
1 
Res Log Li ke 
59 . 96214305 
53 . 14850482 
5 3 . 14593199 
5 3 . 14592672 
Effect 
geno1'age 
geno*age 
geno*age 
geno*age 
conve rgence cr iteri a met . 
Covari ance Parameter 
Estimates 
Cov Parm Esti mate 
l i t  0 . 1063 
Resi dual 0 . 1220 
Fi t stati sti cs 
-2 Res Log Li kel i hood 
AIC (smal l e r  i s  better) 
AICC (smal l er i s  better) 
BIC (smal l er is better) 
Type 
Effect 
3 Tests 
Num 
DF 
1 
1 
1 
1 
1 
1 
1 
of Fi xed Effects 
Den 
DF F val ue 
geno 
age 
geno*age 
s ex 
geno*sex 
age*sex 
geno*age''sex 
geno �ge 0 
0 24 
2 20 
2 24 
27  10 . 77 
27  11 . 06 
2 7  29 . 53 
2 7  0 . 68 
27  0 . 2 5 
27  0 . 01 
27  0 . 01 
Least Squares Means 
Standard 
Esti mate E r ror DF 
1 . 1834 0 . 1870 2 7  
1 .  3636 0 . 1668 27 
0 . 95 5 6  0 . 1847 27  
2 . 28 59 0 . 1692 2 7  
Tests of Effect sl i ces 
Num Den 
5 3 . 1  
57 . 1  
57 . 5  
58 . 1  
cri teri on 
0 . 00033651 
0 . 00000071 
0 . 00000000 
Pr > F 
0 . 0029 
0 . 0026 
< . 0001 
0 . 4173 
0 . 6224 
0 . 9241 
0 . 9409 
t val ue Pr > l t l 
6 . 33 < . 0001 
8 . 17 < . 0001 
5 . 17 < . 0001 
13 . 51 < . 0001 
Effect geno age DF DF F val ue Pr  > F 
geno*age 20 1 2 7  2 . 07 0 . 1616 
geno*age 24 1 2 7  43 . 09 < . 0001 
geno*age 0 1 27  0 . 52 0 . 4783 
geno*age 2 1 2 7  28 . 21 < . 0001 
1 1 0 
Effect 
Dependent vari abl e MT (empty stomach wei ght , grams )  
Iterati on 
0 
1 
2 
3 
Effect 
geno 
age 
Iterati on 
Eval uat ions -2  
1 
3 
1 
1 
Hi story 
Res Log Li ke 
-73 . 48329865 
-74 . 69446273 
- 74 . 69528030 
-74 . 69528104 
convergence c ri teri a met . 
Covari ance Paramete r 
Est i mates 
cov Parm Esti mate 
l i t  0 . 000909 
Resi dual 0 . 004760 
Fi t Stati sti cs 
-2  Res LOT Li kel i hood AIC (smal er i s  better) 
AICC (smal l er i s  better) 
BIC (smal l er i s  better) 
- 74 . 7  
- 70 . 7  
- 70 . 3  
-69 . 7  
Type 3 Tests of Fi xed Effects 
NUm Den 
DF DF F val ue  
1 27  0 . 05 
1 27  27  . 66 
geno;'age 1 27  0 . 71 
sex 1 27  0 . 00 
geno''sex 1 27  1 .  73  
age*sex 1 27 0 . 00 
geno*age''sex 1 2 7  1 .  2 0  
Least Squares Means 
standard 
Esti mate Error DF t 
cr iterion 
0 . 00001124 
0 . 00000001 
0 . 00000000 
Pr  > F 
0 . 8220 
< . 0001 
0 . 4057 
0 . 9 561 
0 . 1993 
0 . 9854 
0 . 2824 
val ue Pr > I t I 
geno*age 6
eno �6
e 
0 . 2664 0 . 02615 27 10 . 19 < . 0001 
geno*age 0 24 0 . 3978 0 . 02331 27  17 . 06 < . 0001 
geno*age 2 20 0 . 2 536  0 . 02587  27  9 . 80 < . 0001 
geno*age 2 24 0 . 4201 0 . 02 393 27  17 . 56 < . 0001 
Tests of Effect sl i ces 
Num Den 
Effect geno �ge DF OF F val ue Pr  > F geno*age 1 27 0 . 17 0 . 6823  
geno*age 24 1 27 0 . 65 0 . 4279 
geno*age 0 1 27  14 . 06 0 . 0009 
geno''age 2 1 27  2 2 . 32 < . 0001 
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Dependent Vari abl e contents (wei ght of stomach contents , grams) 
Iterati on Hi story 
Iteration  
0 
1 
2 
3 
Eval uati ons - 2  
1 
2 
1 
1 
Res Log Li ke 
61 . 24710155 
56  . 18741132 
56 . 17686587 
5 6 . 17678310 
Effect 
geno*age 
geno''age 
geno*age 
geno*age 
convergence cri teri a met . 
covari ance Parameter 
Esti mates 
cov Parm Esti mate 
l i t  0 . 09857  
Resi dual 0 . 1371 
Fit stati sti cs 
-2  Res Log Li kel i hood 
AIC (smal l er i s  better) 
AICC (smal l er is bette r) 
BIC (smal l e r  i s  better) 
Type 3 
Effect 
Tests 
Num 
DF 
1 
1 
1 
1 
1 
1 
1 
of Fi xed 
Den 
DF 
2 7  
2 7  
2 7  
2 7  
2 7  
2 7  
2 7  
Effects 
F val ue 
9 . 29 
7 . 22 
geno 
age 
geno*age 
sex 
geno*sex 
age*sex 
geno*age*sex 
geno �8e 0 
0 24 
2 20 
2 24 
24 . 77 
0 . 74 
0 . 05 
0 . 01 
0 . 02 
Least Squares Means 
Standard 
Esti mate Error DF 
0 . 9220 0 . 1871 27  
0 .  9670 0 . 1672 27 
0 . 7057 0 . 1847 27 
1 . 8665  0 . 1698 27 
Tests of Effect Sl i ces 
Num Den 
56 . 2  
60 . 2  
60 . 5  
61 . 1  
t 
Cri teri on 
0 . 00168990 
0 . 00001392 
0 . 00000000 
Pr > F 
0 . 0051 
0 . 0122 
< . 0001 
0 . 3986 
0 . 82 5 5  
0 . 9116 
0 . 9016 
Val ue 
4 . 93 
5 . 78 
3 . 82 
10 . 99 
Pr > l t l  
< . 0001 
< . 0001 
0 . 0007 
< . 0001 
Effect geno �ge DF DF F val ue Pr > F 0 . 2080 
< . 0001 
0 . 8 590 
< . 0001 
geno*age 1 2 7  1 . 66 
geno*age 24 1 2 7  36 . 50 
geno*age 0 1 27  0 . 03 
geno*age 2 1 27  2 1 . 41 
11 2 
Dependent vari abl e rl8s (18s ri bosomal RNA) 
Iterati on Hi story 
Ite rati on 
0 
1 
2 
Eval uati ons -2  Res Log Li ke 
247 . 20634815 
242 . 96477398 
242 . 96476801 
c ri teri on 
1 
2 
1 
0 . 00000007 
0 . 00000000 
Effect 
geno 
age 
convergence cri te ri a  met . 
covari ance Parameter 
Esti mates 
cov Parm Estimate 
l i t  11 . 3 594 
Resi dual 2 2 . 6420 
Fi t Stati sti cs 
- 2  Res Lal Li kel i hood AIC (smal e r  i s  bette r) 
AICC (smal l er i s  better) 
BIC (smal l er is better) 
243 . 0  
247 . 0  
247 . 3  
247 . 9  
Type 3 Tests of Fi xed Effects 
Num Den 
DF DF F val ue 
1 27  0 . 02 
1 27  0 . 90 
Pr > F 
0 . 8969 
0 . 3 508 
geno*age 1 27 1 . 19 0 . 2840 
sex 1 27  0 . 47 0 . 4969 
geno*sex 1 27  0 . 02 0 . 8847 
age*sex 1 27  0 . 09 0 . 7618 
geno''age*sex 1 27  0 . 22 0 . 6462 
Least Squares Means 
Standard 
Effect geno age Esti mate E r ror DF t val ue 
geno*age 0 20 22 . 5 364 2 . 1813 27 10 . 33 
geno*age 0 24 18 . 5418 1 .  9516 27  9 . 50 
geno*age  2 20 20 . 7749 2 . 1523 27  9 . 65 
geno*age 2 24 19 . 9268 1 .  9882 27  10 . 02 
Tests of Effect sl i ces 
Num Den 
Effect geno �ge DF DF F Val ue geno*age 1 2 7  0 . 67 
geno*age 24 1 27  0 .  52  
geno''age 0 1 27  1 . 86 
geno*age 2 1 27  0 . 08 
1 1 3 
Pr > ! t i 
< . 0001 
< . 0001 
< . 0001 
< . 0001 
Pr > F 
0 . 4 200 
0 . 47 5 3  
0 . 1836  
0 .  7745 
Dependent vari abl e fas (fatty aci d synthase) 
Iterati on Hi story 
Iterat i on 
0 
1 
Eval uati ons - 2  Res Log Li ke 
1 83 . 86814094 
2 8 3 . 86772763 
Effect 
geno*age 
geno*age 
geno*age 
geno*age 
Effect 
geno 
age 
convergence c ri teri a met . 
covari ance Parameter 
Est i mates 
cov Parm Esti mate 
l i t  0 . 001111 
Resi dual 0 . 3885 
Fi t Stati sti cs 
-2  R es LoT Li kel i hood AIC (smal er i s  better) 
AICC ( smal l e r  i s  bette r) 
BIC (smal l e r i s  bette r) 
Type 3 Tests of Fi xed Effects 
Num Den 
DF OF F val ue 
1 2 7  81 . 19 
1 2 7  90 . 26 
geno*age 1 27  76 . 61 
sex 1 2 7  14 . 35 
geno''sex 1 27 18 . 06 .1. 
age*s ex 1 2 7  13 . 31 
geno*age*sex 1 27  16 . 16 
Least squares Means 
Standard 
aeno 
28
e Estimate Er ror OF 
i'.i 0 . 1136 0 . 1978 27 
0 24 0 . 2656  0 . 1741 27 
2 20 0 . 1619 0 . 1977 2 7  
2 24 3 . 5 908 0 . 1806 2 7  
Tests of Effect sl i ces 
Num Den 
83 . 9  
87 . 9  
88 . 2  
88 . 8  
t 
Cri te ri on 
0 . 00000000 
Pr > F 
< . 0001 
< . 0001 
< . 0001 
0 . 0008 
0 . 0002 
0 . 0011 
0 . 0004 
val ue 
0 . 5 7 
1 .  5 3  
0 . 82 
19 . 88 
Pr > j t j  
0 . 5706 
0 . 1387 
0 . 4202 
< . 0001 
Effect geno 
28
e OF DF F val ue Pr  > F 
0 . 8638 
< . 0001 
0 . 5687 
< . 0001 
geno*age 1 27  0 . 03 
geno*age 24 1 2 7  177 . 06 
geno*age 0 1 2 7  0 . 33 
geno*age 2 1 27  163 . 97 
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Dependent vari abl e pparg (peroxi some prol i ferator acti vated receptor gamma) 
Effect 
Ite rati on 
0 
1 
2 
3 
4 
5 
6 
7 
Iteration 
Eval uati ons - 2  
1 
2 
1 
1 
1 
1 
1 
1 
Hi story 
Res Log Li ke 
70 . 16382794 
58 . 18365917 
55 . 3679143 3  
54 . 17569461 
53 . 83609670 
5 3 . 79250837 
5 3 . 79141272 
5 3 .  79141180 
conve rgence cr ite ri a met .  
covari ance Parameter  
Esti mates 
cov Parm Esti mate 
l i t  0 . 3189 
Resi dual 0 . 09211 
Fi t stati sti cs 
- 2  Res Log Li kel i hood 
AIC (smal l e r  i s  better) 
AICC (smal l e r i s  better) 
SIC (smal l e r i s  better) 
Type 3 
Effect 
Tests 
Num 
DF 
1 
1 
1 
1 
1 
1 
1 
of Fi xed Effects 
Den 
DF F val ue 
geno 
age 
geno*age 
sex 
geno*sex 
age*sex 
geno*age*sex 
Least 
Esti mate 
27  41 .  29 
27  6 . 00 
2 7  7 . 60 
2 7  4 . 69 
27  10 . 27 
27  3 . 54 
2 7  11 . 07 
squares Means 
standard 
Error DF 
geno*age g
eno �ge 0 .  5 219 0 . 2731 27 
geno*age 0 24 1 . 12 5 5  0 . 2 380 27  
geno*age 2 20  0 . 8601 0 . 2714 27  
geno*age 2 24 1 .  9722 0 . 2 394 27 
Tests of Effect sl i ces 
Num Den 
5 3 . 8  
57 . 8  
58 . 1  
58 . 8  
Cri teri on 
0 . 44 501442 
0 . 1505 5178 
0 . 04124819 
0 . 00561167 
0 . 00015134 
0 . 00000013 
0 . 00000000 
Pr > F 
< . 0001 
0 . 0210 
0 . 0103 
0 . 0394 
0 . 0035  
0 . 0709 
0 . 002 5  
t val ue Pr > ! t i  
1 .  91 0 . 0667 
4 . 73 < . 0001 
3 . 17 0 . 0038 
8 . 24 < . 0001 
Effect geno �ge DF DF F val ue 
Pr  > F 
geno*age 1 2 7  6 . 00 0 .  0211 
geno*age 24 1 2 7  48 . 01 < . 0001 
geno*age 0 1 2 7  2 . 78 0 . 1072 
geno*age 2 1 2 7  9 . 44 0 . 0048 
1 1 5 
Dependent vari abl e scdl (stearoyl CoA desatu rase 1) 
Iterati on Hi story 
Iterat i on 
0 
1 
2 
Eval uati ons - 2  
1 
3 
1 
Res Log Li ke 
2 9 . 04786022 
2 9 . 00604105 
2 9 . 00604076 
Effect 
geno*age 
geno*age 
geno*age 
geno*age 
convergence cri teri a met . 
covari ance Parameter 
Esti mates 
cov Parm Esti mate 
l i t 0 . 002500 
Res i dual 0 . 08642 
Fi t Stati sti cs 
-2 Res Log Li kel i hood 
AIC (smal ler  i s  better) 
AICC (smal l er i s  better) 
BIC (smal l er i s  better) 
Type 3 
Effect 
Tests 
Num 
DF 
1 
1 
1 
1 
1 
1 
1 
of Fi xed 
Den 
DF 
27 
27 
27 
2 7  
2 7  
27  
27  
Effects 
F val ue 
179 . 59 
78 . 33 
37 . 02 
0 . 8 5 
geno 
age 
geno*age 
s ex 
geno*sex 
age*sex 
geno*age*sex 
geno �5e 0 
0 24 
2 20 
2 24 
4 . 04 
0 . 13 
1 . 19 
Least Squares Means 
Standard 
Esti mate E rror DF 
0 . 06768 0 . 09611 27 
0 . 3631 0 . 08483 27 
0. 7142 0 . 09585  27  
2 . 0849 0 . 08783 27 
Tests of Effect Sl i ces 
Num Den 
29 . 0  
3 3 . 0  
3 3 . 4  
34 . 0  
t 
c ri teri on 
0 . 00000001 
0 . 00000000 
Pr :> F 
< . 0001 
< . 0001 
< . 0001 
0 . 3654 
0 . 0544 
0 . 7214 
0 . 2849 
val ue 
0 . 70 
4 . 28 
7 . 4 5  
2 3 . 74 
Pr > ! t i  
0 . 4873 
0 . 0002 
< . 0001 
< . 0001 
Effect geno 25e DF DF F val ue Pr > F < . 0001 
< . 0001 
0 . 0291 
< . 0001 
geno*age 1 2 7  24 . 12 
geno*age 24 1 2 7  213  . 28 
geno*age 0 1 27  5 . 31 
geno*age 2 1 27  111 . 15 
1 1 6 
Dependent vari abl e Mel (mal i c  enzyme) 
Iterati on 
0 
1 
Iterati on Hi story 
Eval uat ions -2  Res Log Li ke 
1 16 . 19376478 
1 16 . 19376478 
Effect 
geno*age 
geno*age 
geno*age 
geno*age 
conve rgence cri ter i a  met . 
covari ance Parameter 
Esti mates 
cov Parm Esti mate 
1 i t  0 
Resi dual 0 . 06253  
Fi t Stati sti cs 
-2 Res Log Li kel i hood 
AIC (smal l er  i s  better) 
AICC (smal l er i s  better) 
SIC (smal l e r i s  better) 
Type 3 
Effect 
Tests 
NUm 
DF 
1 
1 
1 
1 
1 
1 
1 
of Fi xed Effects 
Den 
DF F val ue 
geno 
age 
geno*age 
sex 
geno*sex 
age*sex 
geno*age*sex 
0
eno �ge 
0 24  
2 20 
2 24  
27  34 . 81 
2 7  42 . 76 
2 7  28 . 34 
27  2 . 38 
2 7  4 . 68 
2 7  2 . 24 
2 7  5 . 39 
Least squares Means 
Standard 
Esti mate Error OF 
0 . 03981 0 . 07908 27 
0 . 1311 0 . 06956 27  
0 .  08312 0 . 07908 27 
0 . 9739 0.  07219 2 7  
Tests of Effect sl i ces 
Num Den 
16 . 2  
18 . 2  
18 . 3  
18 . 7  
t 
c ri te r ion 
0 . 00000000 
Pr  > F 
< . 0001 
< . 0001 
< . 0001 
0 . 1342 
0 . 0395 
0 . 1462 
0 . 0280 
val ue 
0 . 50 
1 . 88 
1 . 05 
13 . 49 
Pr > i t i  
0 . 6187 
0 . 0703 
0 . 3025 
< . 0001 
Effect geno �ge OF DF F val ue Pr  > F 0 . 7016 
< . 0001 
0 . 3938 
< . 0001 
geno*age 1 2 7  0 . 15 
geno*age 24 1 2 7  70 . 68 
geno*age 0 1 2 7  0 . 7 5 
geno*age 2 1 2 7  69 . 21 
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Dependent vari abl e 
Iterati on 
Iterati on 
0 
1 
2 
3 
Eval uati ons - 2  
1 
2 
1 
1 
Lep (l epti n) 
Hi story 
Res Log Li ke 
146 . 38819674 
136 . 65 2 25 391 
136 . 6488 5208 
136 . 64884313 
cri teri on 
0 . 00009341 
0 . 00000025 
0 . 00000000 
Effect 
geno 
age 
Convergence cri teria  met . 
Covari ance Parameter 
Estimates 
cov Parm Esti mate 
l i t  1 . 4867 
Resi dual 1 . 1968 
Fi t Stati sti cs 
- 2  Res Lo� Li kel i hood AIC (smal er i s  better) 
AICC (smal l er i s  better) 
BIC (smal l er i s  better) 
136 . 6  
140 . 6  
141 . 0  
141 . 6  
Type 3 Tests of Fi xed Effects 
Num Den 
DF DF 
1 26  
1 2 6  
F val ue 
44 . 27 
3 . 20 
Pr > F 
< . 0001 
0 . 0854 
geno*age 1 26 9 . 87 0 . 0042 
26  sex 1 4 . 98 0 . 0345 
geno*sex 1 26 0 . 34 0 . 5673 
age*sex 1 26 1 . 40 0 . 2476 
geno''age*sex 1 26  0 . 02 0 . 8931 
Least Squares Means 
Standard 
Effect geno age Esti mate Error DF t val ue 
geno"'age 0 20  0 . 9315 0 . 6586 26  1 . 41 
geno*age 0 24 1 . 3290 0 . 5850  26  2 . 2 7  
geno*age 2 20  2 . 12 31  0 . 6 512 26 3 . 26 
geno1' age 2 24  4 . 6 518 0 . 6075  26  7 . 66 
Tests of Effect Sl i ces 
Num Den 
Effect geno �d
e DF DF F val ue 
geno*age 1 26 5 . 76 
geno;'age 24 1 26  51 . 62 
geno*age 0 1 26  0 . 20 
geno*age 2 1 26  8 . 06 
1 1 8 
Pr > I t ! 
0 . 1691 
0 . 0316 
0 . 0031 
< . 0001 
Pr  > F 
0 . 02 38 
< . 0001 
0 . 6 5 56 
0 . 0087 
Dependent vari abl e Gpam (gl ycerol 3-phosphate acyl transfe rase) 
Iterati on 
0 
1 
2 
3 
4 
5 
Effect 
geno 
age 
Iteration Hi story 
Eval uati ons - 2  
1 
2 
1 
1 
1 
1 
Res Log Li ke 
33 . 05888350 
28 . 65 300436 
2 7 . 79040136 
27 . 57877271 
2 7 . 5 5889803 
2 7 . 5 5863814 
Convergence cri teri a met . 
covari ance Parameter 
Estimates 
Cov Pa rm Esti mate 
l i t  0 . 07571 
Resi dual 0 . 05606 
Fi t stati sti cs 
-2 Res LoT Li kel i hood AIC (smal er i s  bette r) 
AICC (smal l er i s  better) 
BIC (smal l er i s  better) 
Type 3 Tests of Fi xed Effects 
Num Den 
DF DF F val ue 
1 2 7  57 . 09 
1 2 7  7 . 5 5 
geno*age 1 2 7  38 . 30 
sex 1 2 7  o .  39  
geno*sex 1 2 7  8 . 65 
age*sex 1 2 7  0 .  2 1  
geno*age*sex 1 2 7  7 .  7 2  
Least Squares Means 
Standard 
Effect geno 
26
e Esti mate Error DF 
geno*age 0 0 . 1904 0 . 1468 27 
geno*age 0 24 0 . 2473 0 . 1302 27  
geno*age 2 20 0 . 2886 0 . 1452  27  
geno*age 2 24  1 .  2 344 0 . 1317 27  
Tests of Effect sl i ces 
Num Den 
2 7 . 6  
31 . 6  
31 .  9 
32 . 5  
t 
cri teri on 
0 . 03 5 32677 
0 . 00900110 
0 . 00091757 
0 . 00001273 
0 . 00000000 
Pr > F 
< . 0001 
0 . 0106 
< . 0001 
0 . 5 3 50 
0 . 0066 
0 . 6493 
0 . 0098 
val ue  P r > I t I 
1 .  30 0 . 20 5 5  
1 . 90 0 . 0683 
1 .  99 0 . 0571 
9 .  37 < . 0001 
Effect geno 
20
e DF DF F val ue Pr  > F 
geno*age 1 27  0 . 83 0 . 3692 
geno*age 24 1 27  107 . 32  < . 0001 
geno*age 0 1 2 7  0 . 08 0 . 7742 
geno*age 2 1 27  2 3 . 28 < . 0001 
1 1 9 
Dependent Vari abl e Tkt (transketol ase) 
Iterati on  
0 
1 
2 
3 
4 
Iterati on 
Eval uati ons -2 
1 
2 
1 
1 
1 
Hi story 
Res Log Li ke 
66 . 76063509 
6 5 .  71710139 
6 5 . 70152914 
6 5 . 70122878 
6 5 . 70122865 
convergence cri teri a met . 
Covari ance Parameter 
Estimates 
cov Parm Esti mate 
l i t  0 . 06094 
Resi dual 0 . 2119 
Fi t stati sti cs 
-2  Res Log Li kel i hood 
AIC (smal l e r  i s  better) 
AICC (smal l er i s  bette r) 
SIC (smal l er i s  better) 
Type 
Effect 
3 Tests 
Num 
DF 
1 
1 
1 
1 
1 
1 
1 
of Fi xed 
Den 
DF 
26 
26  
26  
26  
26  
26  
26  
Effects 
F val ue 
geno 
age 
geno*age 
s ex 
geno*s ex 
age*sex 
geno*age*sex 
L east Squares Means 
Standard 
18 . 20 
4 . 38 
8 . 89 
0 . 06 
2 .  33 
2 . 5 3 
2 . 56 
65 . 7  
69 . 7  
70 . 1  
70 . 7  
Cri teri on 
0 . 064214 59 
0 . 00128234 
0 . 00000057 
0 . 00000000 
Pr > F 
0 . 0002 
0 . 0464 
0 . 0061 
0 . 8057  
0 . 1389 
0 . 1239 
0 . 1219 
Effect geno age Esti mate E rror OF t val ue Pr > ! t i  
0 . 0213 
0 . 0084 
0 . 0019 
< . 0001 
geno*age 0 20 0 . 4 5 78 
geno*age 0 24 0 . 4764 
geno*age 2 20 0 . 6 391 
geno*age 2 24 1. 5 007 
Tests of 
Effect geno �ge geno*age 
geno*age 24  
geno*age 0 
geno*age 2 
0 . 1868 
0 . 1669 
0 . 1845 
0 . 1779 
Effect sl i ces 
Num Den 
OF OF 
1 26  
1 26  
1 26  
1 2 6  
1 20 
26 
26 
26 
26  
F val ue 
0 . 76 
28 . 50 
0 . 01 
11 . 30 
2 . 4 5  
2 . 85 
3 . 46 
8 . 44 
Pr > F 
0 . 3902 
< . 0001 
0 . 9414 
0 . 0024 
Dependent vari abl e Fdps (farnesyl di phosphate synthase) 
Iterati on 
0 
1 
2 
3 
4 
Effect 
geno 
age 
Ite rati on 
Eval uati ons -2 
Hi story 
Res Log Li ke 
20 . 8 3749854 
17 . 54310505 
17 . 41398343 
17 . 40 5 5 5616 
17 . 405 50477 
1 
2 
1 
1 
1 
convergence cr ite ri a met . 
covari ance Paramete r 
Estimates 
cov Parm Esti mate 
l i t 0 . 03052 
Resi dual 0 . 04930 
Fi t Stati sti cs 
-2 Res LoT Li kel i hood AIC (smal e r  i s  better) 
AICC (smal l er i s  better) 
BIC (smal l er i s  better) 
Type 3 Tests of Fi xed Effects 
Num Den 
DF DF F val ue 
1 27 28 . 81 
1 2 7  13 . 40 
geno*age 1 27  13 . 58  
sex 1 2 7  0 . 94 
geno*sex 1 27  13 . 49 
age*sex 1 27  3 . 11 
geno*age*sex 1 27  9 . 69 
Least Squares Means 
standard 
Effect 8eno 28
e Esti mate Error DF 
geno*age 0 . 2 730 0 . 1076 27 
geno*age 0 24  0 . 4928 0 .  09618 27 
geno''age 2 20  0 . 3860 0 . 1061 27 
geno*age 2 24 1 . 1011 0 . 09781 27 
Tests of Effect s l i ces 
Num Den 
17 . 4  
2 1 . 4  
2 1 .  8 
22 . 4  
t 
c r ite ri on 
0 . 00446460 
0 . 00031731 
0 . 00000202 
0 . 00000000 
Pr > F 
< . 0001 
0 . 0011 
0 . 0010 
0 . 3420 
0 . 0010 
0 . 0891 
0 . 0043 
val ue Pr > i t I 
2 . 54 0 . 0172 
5 . 12 < . 0001 
3 . 64 0 . 0011 
11 . 26 < . 0001 
Effect geno age DF DF F val ue  Pr > F 
geno*age 20  1 2 7  1 .  2 7  0 . 2704 
geno*age 24 1 27  46 . 43 < . 0001 
geno*age 0 1 27  2 . 32 0 . 1393 
geno*age 2 1 2 7  24 . 5 5 < . 0001 
1 21 
Dependent vari abl e Ins igl (i nsul i n  i nduced gene 1) 
Iterati on Hi story 
Iterati on 
0 
1 
Eval uati ons -2  Res Log Li ke 
1 44 . 38680636 
1 44 . 38680636 
C ri te ri on 
0 . 00000000 
convergence cri teri a met . 
covari ance Parameter  
Estimates 
cov Parm Esti mate 
l i t  0 
Resi dual 0 . 1425  
Fi t Stati sti cs 
-2 Res Log Li kel i hood 
AIC (smal l er i s  better) 
AICC (smal l er i s  better) 
BIC (smal l e r i s  better) 
44 .4  
46 . 4  
46 .  5 
46 . 9  
Type 3 
Effect 
geno 
age 
geno''age 
sex 
geno*sex 
age*s ex 
geno*age*sex 
Tests 
Num 
OF 
1 
1 
1 
1 
1 
1 
1 
of Fi xed 
Den 
OF 
25 
25 
25 
25 
2 5  
2 5  
2 5  
Effects 
F val ue 
14 . 19 
2 2 . 76 
4 . 11 
0 . 99 
8 . 65 
4 . 01 
9 . 44 
Least squares Means 
Standard 
Effect 
6
eno �ge Esti mate Error DF geno''age 0 . 2086 0 . 1379 2 5  
geno*age 0 24 0 . 5 3 36 0 . 1050 25  
geno*age 2 20 0 . 4146 0 . 1194 2 5  
geno*age 2 24 1. 2203 0 . 1090 �5  
Tests of Effect sl i ces 
Num Den 
Effect geno �ge DF DF F geno*age 1 2 5  
geno*age 24 1 2 5  
geno''age 0 1 25  
geno*age 2 1 2 5  
1 22 
t 
Pr > F 
0 . 0009 
< . 0001 
0 . 0533  
0 . 3293 
0 . 0070 
0 . 0562 
0 . 0051 
val ue 
1 .  51 
5 . 08 
3 . 47 
11 . 20 
val ue 
1 .  28  
2 0 .  58  
3 . 52 
24 . 84 
Pr > i t i  
0 . 1428 
< . 0001 
0 . 0019 
< . 0001 
Pr  > F 
0 . 2695 
0 . 0001 
0 . 0725 
< . 0001 
Dependent vari abl e Lpl (l i poprotei n l i pase) 
Effect 
Iterati on 
0 
1 
2 
3 
4 
5 
Iteration 
Eval uati ons -2  
1 
2 
1 
1 
1 
1 
Hi story 
Res Log Li ke 
62 . 2 5696858 
58 . 74797299 
58 . 34160656  
58 . 258 59092 
58 . 2 5418206 
5 8 . 2 5416553  
convergence c ri teri a met .  
Covari ance Parameter 
Esti mates 
cov Parm Esti mate 
l i t  0 . 18 5 7  
Resi dual 0 . 1465 
Fi t Stati stics 
- 2  Res Log Li kel i hood 
AIC (smal ler  i s  better) 
AICC (smal l er is better) 
BIC (smal l er i s  better) 
Type 3 
Effect 
Tests 
Num 
DF 
1 
1 
1 
1 
1 
1 
1 
of Fi xed 
Den 
DF 
24 
24 
24 
24 
24 
24 
24 
Effects 
F val ue 
12 5 . 88 
1 .  31  
geno 
age 
geno*age 
sex 
geno*sex 
age*sex 
geno*age*sex 
geno age 
L east 
Esti mate 
squares Means 
Standard 
E rror 
11 . 32 
2 . 09 
0 . 06 
0 . 21 
2 . 5 3 
DF 
geno*age 0 20 0 . 4155  0 . 2 362 24 
geno*age 0 24 0 . 3328 0 . 2 119 24 
geno*age 2 20 1.  3842 0 . 2295  24  
geno*age 2 24 2 . 1315 0 .  2139 24 
Tests of Effect Sl i ces 
Num Den 
58 . 3  
62 . 3  
62 . 6  
63 . 2  
cri teri on 
0 . 1764 5 505  
0 . 03528263 
0 . 002005 5 2  
0 . 00000779 
0 . 00000000 
Pr > F 
< . 0001 
0 . 2638 
0 . 0026 
0 . 1613 
0 . 8033 
0 . 6 519 
0 . 1248 
t val ue Pr > ! t i  
0 . 0913 
0 . 1293 
< . 0001 
< . 0001 
l .  76 
1 . 57 
6 . 03 
9 . 96 
Effect geno �ge . DF DF F val ue P r  > F < . 0001 
< . 0001 
0. 7966 
0 . 02 5 5  
geno*age 1 24 29 . 00 
geno*age 24 1 24 113 . 59 
geno*age 0 1 24 0 . 07 
geno*age 2 1 24  5 . 67 
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